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Foreword and Accompanying Statement By
Joseph A. Califano, Jr.
Chairman and President
Open a newspaper or turn on the TV and you
will find a story on drug use in sports.  In their
consuming ambition to win, too many athletes
use a complex array of substances to enhance
their performance--a practice that has come to be
known internationally as doping.  The CASA
National Commission on Sports and Substance
Abuse has found that in Olympic competition,
the high financial stakes for athletes and their
families, corporate sponsors, broadcast and cable
industries and organizations that manage and
govern sports put a big thumb on the side of the
scale that encourages doping.  Coaches, trainers,
team mates and even parents share a win at any
cost mentality that often encourages athletes to
dope.
Along with big bucks involved, the explosion in
performance-enhancing substances and lack of
any effective and independent mechanism to
police the use of banned substances in training
as well as competition, threatens the integrity of
Olympic Games.
While doping may help break records, hype
games and sell products, it has a dark physical
and moral underbelly.  Unlike better gear, better
nutrition or better training, ingesting and
injecting performance-enhancing substances
jeopardizes the health of athletes.  Because
athletes are second in importance only to parents
as role models for children, doping by sports
heroes also threatens the health of our children
who follow the example set by elite athletes.
This report sets out the compelling evidence of
their adverse health consequences.
Doping perverts the meaning and core values of
sport, undermines the legitimacy of competition
and sends messages to our children that winning
at any cost is the highest value.  The practice of
doping mocks the Olympic Creed:  "The most
important thing in the Olympic Games is not to
®
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win but to take part, just as the most important
thing in life is not the triumph but the struggle."
To better understand substance abuse in sports,
the environment that promotes such abuse and
the effects such abuse has on children, CASA
created The CASA National Commission on
Sports and Substance Abuse.  This 15 member
Commission chaired by University of Notre
Dame President Reverend Edward A. (Monk)
Malloy and composed of a distinguished group
of citizen members, has been conducting the
first extensive national analysis of the
relationship between substance abuse and sports
at the high school, college, professional and
Olympic levels.
This initial CASA Commission report is the
result of two years of intensive research.  Its
focus is on Olympic competition, primarily from
the U.S. perspective.  Subsequent Commission
reports will examine substance abuse and
American sports at the professional, collegiate
and high school levels, explore methods of
doping prevention and survey the attitudes and
opinions of U.S. Olympic athletes.
The CASA Commission found that estimates of
athletes' use of performance-enhancing drugs in
Olympic sports vary widely--from less than
three percent to more than 90 percent--
depending on whether one asks organizations
responsible for the sport, athletes, coaches or
trainers.  What most parties involved in Olympic
Sports do agree is that doping is a serious
problem for the Olympics and must be
eliminated to preserve the integrity of the
competition.
Since many of the drugs used do enhance
performance, governing bodies in Olympic sport
face a conflict of interest between two of their
primary goals:
• Promoting sport, with its premium on
breaking records to attract and hold sponsors
and capture a world audience essential to
financial growth; vs.
• Preserving the integrity of athletic
competition by policing and sanctioning
those who use banned performance-
enhancing substances.
The crazy quilt of jurisdictions responsible for
anti-doping policies and practices--the
International Olympic Committee, International
Sports Federations, National Olympic
Committees, National Governing Bodies, the
World Anti-Doping Agency created in 1999 to
coordinate an international anti-doping program,
and national anti-doping agencies, each with its
own independent view--assure inconsistency in
applying any rules.  The aura of secrecy in
which these bodies squirrel test results invites
public cynicism about the integrity and the
meaning of record-breaking Olympic
performances.  The absence of an independent
international organization with no financial stake
in sport and with authority to draft and enforce a
consistent and fair anti-doping program is
eroding public confidence in the Olympics.
Societies should celebrate athletic
accomplishment as a triumph of human body,
mind and spirit.  Instead, societies seem
obsessed with winning.  Vince Lombardi told us
"winning isn't everything--it's the only thing."  A
Nike ad put it this way:  "You don't win the
silver--you lose the gold."  The legendary Knute
Rockne cracked, "Show me a good and gracious
loser and I'll show you a failure."  If our children
and athletes buy into this "win at any cost"
philosophy, then for them the end of winning
will justify any means, including doping.
Getting doping out of Olympic sports will
require a determined and collective exercise of
political will.  All the players will have to put
their oars in the Olympic waters:  national
governments, corporate executives,
broadcasters, cable companies, coaches, trainers,
parents and athletes.  It will require the
establishment of a truly independent
organization with authority for doping control in
Olympic sports.  It is time for the Olympic
players to come out of the maze of bureaucratic
agencies and recognize and shed the conflicts of
interest that have spurred increased doping.
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Participants in the Olympic movement must step
out of the darkness of secrecy that undermines
credibility and take the world Olympic games
into the sunlight of fair competition that truly
measures human achievement unadulterated by
performance-enhancing substances.  This report
provides recommendations to do just that.
The recommendations and the work of the
CASA Commission stem from a recognition of
the significance of the Olympic Games to the
people of the world over many generations and
the importance of maintaining the integrity of
the Olympics as a model of achievement in fact
and in appearance.
For the financial support that made this
undertaking possible, the Board of Directors of
CASA and our staff of professionals extend our
appreciation to the White House Office of
National Drug Control Policy, the Abercrombie
Foundation and The Henry J. Kaiser Family
Foundation.
Special gratitude goes to Monk Malloy for
chairing this Commission, as he has so ably
done for two previous CASA Commissions--
Substance Abuse and The American Adolescent:
A Report by the Commission on Substance
Abuse Among America's Adolescents (August
1997) and Rethinking Rites of Passage:
Substance Abuse on America's Campuses, A
Report by the Commission on Substance Abuse
at Colleges and Universities (June 1994).  We
are indebted for the time and effort put in by
other Commission members and technical
advisors.  Margaret Mahoney, former President
of The Commonwealth Fund, deserves mention
for first bringing to my attention the importance
of delving into sports and substance abuse and
insisting that CASA take on this task.  We also
appreciate the time, expertise and candor of the
individuals intimately involved with sports who
met and spoke with Commission members and
staff during the course of the Commission's
deliberations.  Their firsthand knowledge of
sports and the issues surrounding doping in
sports were invaluable, if often disturbing.
We wish to thank General Barry R. McCaffrey
for his commitment to reducing doping in
Olympic sports and his dedication to a drug-free
society.  We applaud his leadership and
dedication and acknowledge the support and
assistance of staff of the Office of National Drug
Control Policy and consultants Dr. J. Michael
Walsh and Scott H. Green.  Attorneys from
Dewey Ballantine, CASA's counsel, helped
analyze the legal issues.
Donald S. Frederickson, M.D., former Director
of the National Institutes of Health and former
President of the Institute of Medicine, and
Herbert D. Kleber, M.D., CASA's Executive
Vice President and Medical Director, co-chaired
the Technical Advisory Group to the
Commission.  Susan E. Foster, M.S.W., CASA's
Vice President and Director of Policy Research
and Analysis, is the principal investigator and
staff director for this effort.  They were ably
assisted by CASA Research Associates Arsenio
G. DeGuzman, Jr., M.P.A., and Darshna P.
Modi, M.P.H.  David Man, Ph.D., CASA's
librarian, and library assistants Barbara
Kurzweil and Ivy Truong were a big help.  Jane
Carlson, once again handled the administrative
chores with efficiency and good spirit.
While many people contributed to this effort, the
opinions expressed herein are the responsibility
of The CASA National Commission on Sports
and Substance Abuse.
Joseph A. Califano, Jr.
Chapter I
Introduction and Executive Summary
Since the beginning of the Olympic Games in
Ancient Greece, athletes have sought
competitive advantage through pharmacology.
In the third century BC, Greek athletes ingested
mushrooms in attempts to improve their
performance.1  Egyptians ingested the ground
rear hooves of the Abyssinian mule for its
purported performance-enhancing properties.
Roman gladiators took stimulants to overcome
fatigue while fighting in the famed Circus
Maximus (circa 600 BC).2
In the second half of the 20th century,
pharmacological advances and enormous leaps
in biomedical research have created an
opportunity for performance enhancement
previously unimagined.  In their consuming
ambition to win, many athletes are taking
advantage of this knowledge, often encouraged
to do so by coaches, trainers, team members and
parents.  For the athlete, the win brings
worldwide visibility and claims to big bucks.
But the pharmacological competitive advantage
may in fact be fools' gold, since it threatens the
athlete's health and sends damaging messages to
our children.  For sports governing bodies, tacit
approval of performance-enhancing drugs places
their credibility in jeopardy.  For society itself,
what is at stake is the integrity and meaning of
sport and the future health and ethical values of
a generation of children.
This report is the result of two years of intensive
research.  To enhance its understanding of the
biomedical aspects of performance-enhancing
drug use in sport, the Commission formed a
Technical Advisory Group (TAG).  This
advisory group was comprised of several of the
foremost experts in the fields of sports medicine,
exercise science, pharmacology and biomedical
ethics.  Dr. Donald Frederickson, former
Director of the National Institutes of Health and
former President of the Institute of Medicine,
and Dr. Herbert Kleber, CASA's Executive Vice
President and Medical Director, co-chaired the
®
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TAG.  The TAG's purpose was to advise the
Commission on:
• How performance-enhancing substances
banned by the sports leagues work in the
human body.
• How, from a pharmacological perspective,
athletes use banned substances to enhance
performance and what they hope to gain.
• Potential side effects of performance-
enhancing substances used by athletes.
• Reliability and validity of testing procedures
and practices.
The Commission conducted an extensive review
of relevant literature, held personal interviews
and hearings with sports representatives and
consulted experts in fields related to the use by
athletes of performance-enhancing substances--a
practice known in international sports
competition as doping.  The Commission
reviewed more than 600 articles in the fields of
sociology, law, medicine, pharmacology,
toxicology, business and economics as they
relate to sports.  The backgrounds, histories and
regulatory rules and practices of each of the
sports' governing bodies were examined
thoroughly.  The Commission surveyed public
and media reports (both nationally and
internationally) on a daily basis to track
developments related to performance-enhancing
substance abuse in sports.
The result of this effort is the most
comprehensive review to date of doping in
Olympic sports.*  Key findings include:
* This report focuses on Olympic level athletes--also
called elite athletes.  These are athletes who are
endorsed by the appropriate National Organizing
Committee and/or International Federation to
compete in world-class events, including the
qualifying trials for the Olympic games.  Olympic
athletes are a sub-set of Olympic level athletes who
qualify for the Olympic Games.
• While no one in the Olympic movement
seriously advocates doping by athletes, the
high financial stakes for Olympic athletes,
corporate sponsors, the TV broadcast and
cable industries and sports governing
bodies,† coupled with the pharmacopoeia of
performance-enhancing substances, the
athlete's drive to win and the absence of an
effective policing mechanism, create an
environment that encourages doing
anything--including doping--to win.
• Parents, coaches and trainers often join the
rush for the gold, passively by turning the
other way or actively supporting the use of
performance-enhancing substances.
• National governments covet the gold as a
source of national patriotism and pride and
too often have turned a blind eye to means
athletes use to attain the prize.
• Use of performance-enhancing substances in
sport threatens the health of our athletes, the
integrity and meaning of the sport and the
health and ethical values of our children.
• Children mimic athletes through the
ingestion of potentially harmful and
dangerous substances.  Athletes are second
only to parents in the extent to which they
are admired by children.  Seventy-three
percent of surveyed youth in a study by The
Kaiser Family Foundation look up to and
want to be like some famous athletes; 52
percent think that it is common for famous
athletes to use steroids or other banned
substances in order to get an edge on the
competition.
• "Clean" athletes face three choices:
(1) compete without using performance-
enhancing substances, knowing that they
may lose to competitors with fewer scruples;
† The International Olympic Committee, the
International Sports Federations, the National
Olympic Committees and the National Governing
Bodies.
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(2) abandon their quest because they are
unwilling to use performance-enhancing
substances to achieve a decisive competitive
advantage; or (3) use performance-
enhancing substances to level the playing
field.3
• Estimates of prevalence of doping in
Olympic sports vary widely.  The lowest
estimates, believed substantially to
underestimate drug use, come from the
testing results of the governing bodies.
These results suggest that less than three
percent of athletes dope.  Some veteran
athletes put the figure closer to 30 percent
and in cycling doping rates have been
documented at 45 percent.4  Some athletes,
coaches and trainers believe that as many as
80 or 90 percent of athletes in some
Olympic sports engage in doping.5
• The main performance-enhancing drugs
used by Olympic athletes are anabolic
steroids, stimulants, beta-2 agonists, human
growth hormone, insulin-like growth factor
and erythropoietin.  Nutritional
supplements--such as creatine,
androstenedione or 19-norandrostenedione
and beta-hydroxy beta-methylbutyrate
(HMB)--also are used for performance-
enhancement.  Athletes may abuse
nonperformance-enhancing drugs such as
alcohol or marijuana.
• Athletes employ a variety of methods to beat
drug tests including the use of diuretics,
adulterants and catheterization.
• Because doping can help athletes break
records and perform amazing feats, Olympic
governing bodies face a conflict of interest
between the goals of promoting sport,
including the ability to attract and keep
sponsors and capture a world audience, and
of preserving integrity and meaning in sport
by policing doping practices.
• Not withstanding the creation in 1999 of the
World Anti-Doping Agency (WADA) to
coordinate an international anti-doping
program, there is no independent and
accountable international organization with
authority to create and administer an
effective anti-doping program for Olympic
sports--during training as well as during
competition.  The WADA has only authority
to make recommendations to the
International Olympic Committee (IOC).6
Getting doping out of sports will require the
political will of all involved.  The national
governments must demand change and the
creation of needed anti-doping standards and
systems.  To these ends, The CASA National
Commission on Sports and Substance Abuse
presents the following roadmap:
• Participant nations--and the other key
players--should demand that Olympic
level athletes be free of performance-
enhancing substances.  Nations must
garner the political will to act in order to
protect the health of athletes, preserve the
integrity of sport and send positive messages
to children.  They must lead the way to build
support for getting doping out of sports.
Parents who organize and promote athletic
events for their children should send clear
messages against doping in sports.  Current
and former Olympic athletes should be
enlisted to demand and support anti-doping
policies.  Coaches and trainers should set
anti-doping standards and reinforce them
with positive messages of substance-free
competition.  Corporate sponsors should
show leadership by championing drug-free
sports and by demanding that athletes be
substance-free for the games they sponsor.
• Participant nations should ensure that an
independent international organization
exists with authority over the methods of
measurement and sanctions for doping in
Olympic sports.  This organization would
not report to the IOC or any sport governing
body.  It would have responsibility over the
types of substances to ban; the types of tests
to be conducted; the timing of those tests,
the sample collection, analysis and reporting
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processes; adjudication referral and
adjudication.  This organization should
develop consistent standards for the
detection of performance-enhancing
substances and sanctions for their use, and
assure consistent use of these standards and
sanctions throughout the Olympic
movement.  The IOC should commit a
percentage of its overall budget to support
this effort.
• Conduct research needed to determine
long-term consequences of use of
performance-enhancing substances.
Priorities for research to determine the long-
term consequences of performance-
enhancing substances include:  the health
effects of products that are sold as
nutritional supplements, especially
androstenedione, creatine and ephedrine;
and the efficacy and long-term effects of
steroid use, including precursor substances.
• Expand and improve cost-effective
testing.  Priorities to expand and improve
cost effective testing include: an
international collaborative effort, funded
over a five-year period at a total of at least
$50 million to $100 million, to find and
develop reliable tests to detect the use of the
major performance-enhancing drugs;
inexpensive testing procedures for steroids;
cost-effective methods to detect use of
human growth hormone (hGH) and insulin-
like growth factor (IGF-1); and methods of
keeping pace with the development of new
drugs as they emerge.  Testing should be
done on the basis of the best available
technology, whether it is a test for a
substance in the urine, blood, hair, sweat or
oral fluids or is a test of the performance-
enhancing effects of a substance.  Research
should be peer-reviewed to assure credibility
and increase acceptability in the
adjudication process.
• Conduct comprehensive out-of-
competition testing.  Comprehensive out-
of-competition testing is essential to an
effective doping program.  Event or in-
competition testing is useful for detecting
substances that provide relatively fast-acting
performance benefits for the user (e.g.,
stimulants to delay or reduce fatigue).
However, many substances provide the
greatest benefits to athletes when used
during training (e.g., steroids to increase
muscle mass).  If only in-competition testing
is used, athletes may cease using a banned
substance in sufficient time to clear its
metabolites from their systems.  The only
way to detect use of these banned training
drugs is through a no-advance notice, out-
of-competition testing program.
• In the United States, strengthen the
provisions of the Dietary Supplement
Health and Education Act of 1994.
Athletes claim that they may unknowingly
take banned substances in unlabeled or
poorly labeled nutritional supplements.
Congress should require manufacturers of
dietary supplements to identify all contents
and to label their products accurately.
Concerns about youth mimicking athletes'
behavior and ingesting substances which
may be harmful or for which long-term
effects are unknown provide another reason
for Congress to act.  Any claims of results
now permitted under the Act related to
structure and function should be supported
by peer-reviewed research.  Congress should
consider regulating testosterone precursors
as drugs rather than as nutritional
supplements.
• Adopt Athlete Passports.  A "doping
passport"* 7 is an accessible and public
history of an athlete's doping tests.8  Health
histories of athletes, with hormone levels,
hematocrits and other data spanning several
years can be incorporated into this
document.9  Such a passport could rectify
the situation of athletes who are unfairly
penalized for having natural hormone or
other biochemical levels outside the range of
what is considered normal (e.g., athletes
* Proposed by the IOC Athletes Commission which is
responsible for acting as the mediator between active
Olympic athletes and the IOC.
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who naturally have a hematocrit over 50).
Publically available passports would provide
the type of open record necessary to help
restore the integrity of sport.
• Adopt a standard protocol for
establishing the banned substances list.
To determine which substances to ban in
Olympic competition, an independent
organization should adopt an open and
public process based on current scientific
evidence and grounded in consistently
applied rules.  This process should be
applied to new candidate substances as they
are developed  and eventually to the current
list of banned substances in order to identify
those to be added or removed.
-6-
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Chapter II
What's at Stake?
Sports are among the most popular leisure
activities in the world today.  As a social
institution, sports help to fill individuals' need
for exercise, tension release, diversion and
entertainment.1  Sport is the play of the spirit,
the challenge of the mind and the perfection of
the body.2  Sports are also avenues to fame and
to fortune and engines to drive corporate profits.
In Olympic sports, high economic stakes and
chances for worldwide visibility compound the
athlete's drive for competitive advantage.
Winners secure tidy contracts for corporate
product endorsements.  These endorsements in
turn increase corporate profits.  To ensure these
profits, corporations underwrite costs of the
games securing their importance to the
governing bodies of sports.  These high stakes,
coupled with the fact that sports are sources of
national and international pride and patriotism,
create an environment that encourages doping.
But there are serious downsides.  Use of
performance-enhancing substances in sport
threatens the health of our athletes, the integrity
and meaning of the sport itself and the health
and ethical values of our children.
The Role of Sports in Society
Americans' appetite for sports appears to be
nearly insatiable.  An estimated one-half of the
United States population participates in various
sporting activities regularly.  In the United
States, the number of spectators who attended
sports events in 1995 reached 272 million.* 3
According to one study done in the United
States, 62 percent of parents say that their
children participate in organized sports.
Seventy-five percent of American parents
frequently encourage their children to engage in
sports.4
* These events included professional baseball,
basketball, football and hockey; college football and
basketball; thoroughbred and greyhound racing; and
jai alai.
®
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Sports permeate virtually every social
institution.  Throughout countries worldwide,
sports also are linked inextricably with other
social institutions in a web of mutually
reinforcing relationships.  Sports socialize
children and provide a source of family
recreation.  The family provides a source of
players, parental encouragement and financial
support through transportation, fees, and
equipment.  Sports are a source of school spirit
and cohesion, an outlet for adolescent energy
and an insulation against delinquency.  Schools
reinforce the importance of sports through
trophies, rallies and assemblies, and provide a
training ground for elite athletes.5
Sports provide profits for television, radio and
newspapers; profits for manufacturers of sports
apparel and equipment; and spin-off dollars for
restaurants, bars, hotels and transportation.
They also help feed the multi-billion dollar
fitness industry (i.e., nutritional and dietary
supplement manufacturers and distributors, and
the publishers of fitness magazines).
Corporations support sports by sponsoring teams
or athletes, purchasing blocks of season tickets
and manufacturing products with team emblems
that pay back royalties.6
Sports reinforce patriotism and citizenship
through flag raising, color guards and the
national anthem.  They also promote a sense of
national identity, pride, belonging and unity.
Sports are protected by antitrust exemptions,
favorable tax laws and government subsidies to
stadiums.  Many political leaders endorse sports.
Sports use team chaplains and reinforce
traditional morality through the athletic creed.
Churches sponsor athletic leagues and reinforce
sports through the use of athletic metaphors in
sermons and religious writings.7
Sports news often receives at least as much
coverage as news about business, culture and
public affairs.  In the United States, on network
television alone (i.e., not including cable
service) sporting events constitute about 15
percent of all telecasts.  In 1995, networks
broadcast 2,000 hours of sports, and some cable
providers (e.g., ESPN and ESPN2) broadcast
sports nearly 24 hours a day.8  Sports even have
played a role in advancing understanding and
goodwill among nations.
Olympic sports represent the epitome of athletic
performance--the highest goal to which an
athlete can aspire.  But the medals of Olympic
sports are tarnished by the practices of doping in
all its forms.  What drives athletes to participate
in doping?  What are the social and economic
reinforcements to doping practices and what are
its consequences?
What's at Stake for the Athlete?
Each athlete strives to improve performance by
better training, better mental focus, better
nutrition, better clothing, better gear.  Increases
in technology have made possible, for example,
clothing that can reduce wind or water resistance
and shave a few seconds off a race, or shoes that
can increase the lift in a jump.  Advances in our
understanding of physiology enable us to
develop training protocols and dietary plans to
improve strength and endurance.  From there it
is just a small step to using nutritional
supplements or drugs to accomplish even more
significant performance advancements.  Because
of this inevitable search for improvement, some
may argue that doping is conceptually no
different than better gear or better diet.
Doping, however, presents a much more
complex issue.  For example, unlike training,
nutrition and better gear, performance-enhancing
drugs may threaten the health and future well-
being of the athlete and may encourage children
to follow suit.  As discussed in Chapter 3, The
I'm going to wear it till I die...Do I think it
helped me get the world record?  Yes.  Do I
think I would have gotten it without it?  No.
Do I think I would eventually get the world
record without it?  Yes.  ...It feels like you're
sliding through the water...You feel like I
imagine a shark does.9
--Tom Malchow, elite level swimmer
who set the world record
in the 200 meter butterfly
in June wearing a bodysuit
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Pharmacology of Competition, some
performance-enhancing drugs are known to have
adverse health effects; others have unknown
effects.  But many athletes, spurred on by
coaches and trainers, family and friends and the
lure of the win, disregard these potential effects
and ignore the ethical questions their use raise.
One athlete's decision to use performance-
enhancing drugs also exerts a powerful effect on
the other athletes in the competition.  As
reported by Sports Illustrated, half of all
recently surveyed Olympic athletes admitted that
they would be willing to take a drug--even if it
would kill them eventually--as long as it would
let them win every event they entered five years
in a row.* 10  This type of "win at any cost"
mentality is pervading sports at all levels of
competition and results in athletes feeling
coerced to use substances just to remain on par
with other athletes.
Helping to drive this competitive rush is the lure
of international acclaim and financial rewards.
For some, the monetary values of these items
can climb to millions of dollars long after the
end of a race or competition.  Thus, the potential
for financial gain raises the stakes for athletes
considerably.  For example:  medal winners in
the Olympic Games and other international
sports events receive worldwide attention and
adulation and command lucrative endorsement
contracts:
* This survey of 198 Olympic athletes was performed
by Dr. Robert Goldman during the 1996 Summer
Olympic Games in Atlanta.  Currently, Dr. Goldman
is a sports medicine physician in private practice in
Chicago.  At the time of publication, CASA was
unable to retrieve data or supporting documentation
for these survey results from Dr. Goldman.
• Lance Armstrong, two-time winner of
cycling's premier race, the Tour de France,
receives $5 to $7.5 million annually from
endorsements.12
• Brandi Chastain, a forward for the U.S.
Women's Soccer Team that won the 1999
Women's World Cup, recently signed multi-
year endorsement deals worth $2 million.13
• Michelle Kwan, Olympic figure skating
champion, earned nearly a quarter of a
million dollars in prize money during the
past winter season, an estimated six figures
in appearance fees, another six figures in
endorsements, and more than $300,000 for
skating in the Champions on Ice tour.14
• Maurice Greene, U.S. Track and Field star,
saw his income quadruple between 1997 and
1998, and triple annually since then.  In
1997, he earned about $300,000; he brought
in $1.2 million in 1998 and more than $3
million in 1999.  Additionally, he commands
$100,000 a race in Europe; video-game
maker Konami gave him $30,000 to place
his likeness on the cover of its new Track
and Field 2000 game; and Nike, Powerade
and Home Depot either have signed or are
actively recruiting him for endorsement
deals.15
• Marion Jones, U.S. Track and Field star,
earned more than $2.5 million in 1998.  Her
prize money totaled $850,000.  Appearance
fees and an endorsement contract with Nike
comprised the remainder.  According to
sports marketers, she has million-dollar
endorsement potential if factors like
charisma, likability, and the winning of four
or five Olympic gold medals were to come
together.16
National Olympic Committees and National
Governing Bodies offer extra incentives.  For
example, the U.S. Olympic Committee pays a
bounty to athletes of $15,000 for gold medals,
$10,000 for silver, and $7,500 for bronze.  USA
Swimming hands out $50,000 for gold medals,
For two years, I took EPO, growth
hormone, anabolic steroids, testosterone,
amphetamine.  Just about everything.  That
was part of the job.11
--Erwan Mentheour, Cyclist
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$25,000 for silver, and $10,000 for bronze.  In
1996, U.S. swimmers took home more than $1
million in prize money from the United States
Olympic Committee (USOC) and USA
Swimming.17
The drive to win often starts early, with parents
pressuring children to perform, even passively
looking the other way or actively encouraging
performance enhancement in all its forms.
Coaches and trainers pick up the baton in
elementary and high school, often promoting the
use of performance-enhancing substances.  Even
nations, caught up in patriotism and national
pride, often look the other way when it comes to
doping.
Athletes who engage in doping can be perceived
as either villains or victims.  From one
perspective, most elite level athletes are
autonomous adults capable of evaluating the
benefits and risks of taking banned performance-
enhancing substances.  This view places the
majority of blame for doping on athletes.  From
another perspective, athletes are part of a larger
system that coerces them into doing whatever it
takes to win, including the use of banned
performance-enhancing substances.  While not
negating the responsibility athletes have for
doping incidents, this view better reflects the
circumstances of athletic competition.
Elite athletes often couple extraordinary natural
gifts with intense discipline and commitment,
usually forsaking a great deal of time and money
in order to perfect their athletic abilities.  When
faced with the prospect of competitors holding
an advantage based on their willingness to use
performance-enhancing substances, athletes
remain free to choose whether or not to violate
the rules of sport as their competitors may be
doing.  They may not, however, retain their
confidence that the best athlete will win.19
Athletes know that some of these substances do,
indeed, enhance performance.  They may
believe that other substances have these effects
even if objective evidence is lacking.  Many
substances are marketed to athletes as
performance-enhancing even though little
information of any type is available on their
effects.
"Clean" athletes are faced with three choices:
(1) compete without using performance-
enhancing substances, knowing that they may
lose to competitors with fewer scruples;
(2) abandon their quest, unwilling to use drugs
to achieve a decisive competitive advantage; or
(3) use performance-enhancing substances to
level the playing field.21  Paradoxically, the
twisted consequence of this third option is the
escalation of a pharmacological race that would
ultimately result in no one gaining any
competitive advantage, yet everyone suffering
from the long-term effects of these substances.
Even those who use performance-enhancing
substances but stay just short of the technical
line of cheating may run this risk.
What's at Stake for the Governing
Bodies of Sport?
The athletes are only part of the doping puzzle.
The administrative organizations governing
international sports have an enormous stake in
the outcome of athletic competition.  These
We now have to face the reality that the
Olympics constitute not only an athletic event
but a political event.18
--Peter Ueberroth
President of the Los Angeles
Olympic Organizing Committee for
the 1984 Summer Olympic Games
When I was young, I would always go up to
guys and ask, "What kind of workouts do you
do?"  But this kid actually walked up and
asked us what kind of supplements we were
taking...What is this sport coming to?20
--Johnny Gray, four time Olympian and 1992
bronze medalist in track and field after being
approached by a youth at the Los Angeles
Invitational indoor meet last winter
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organizations* have two fundamental goals:  the
promotion of sport, including the ability to
attract and keep sponsors and capture a world
audience, and the preservation of what is
valuable and meaningful in sport by policing
doping practices.  These goals are not always
compatible.  Over the past three decades, the
public has heard the governing bodies of
Olympic sports repeat, reinforce and amplify
their commitment to eliminating drugs from
sport.  Yet, persistent patterns of irregularities in
enforcement raise serious doubts about the
commitment of the sports' governing bodies to
protect the interests of honest athletes, the
virtues of sport and the health and safety of the
competitors.
Many athletes and others involved with
international sport believe that the existing anti-
doping systems (see Chapter 5, The Rules:
Standards and Enforcement) are public relations
tools, not effective counter-drug programs.
Moreover, many athletes believe that these
systems are run in such a way as to catch
unknown athletes--but not stars or potential
medalists.23  A gap of confidence in the ability
of the governing bodies in sport to prevent,
detect and punish drug use in sport has emerged.
Consider the following:
• At both the 1996 Atlanta Games and the
1984 Los Angeles Games, the IOC failed to
act on a series of positive drug test results
for banned substances among medal
winners.  During the Atlanta Games, only
* The International Olympic Committee (IOC),
International Sports Federations, National Olympic
Committees and National Governing Bodies.
two positive test results were announced.
However, in an interview with the London
Sunday Times, Dr. Don Catlin, Director of
the IOC-accredited laboratory performing
the testing for these Games, stated that there
were several other positive test results that
the lab reported to the IOC.  In each of these
instances, lab officials reported that the
samples were passed along to the Director of
the IOC's Anti-Doping Program, Prince
Alexandre de Merode.  Prince de Merode
has publicly stated that he discarded samples
for unstated "technical difficulties."  Neither
the lab reports, the names of the athletes in
question, nor the purported technical
difficulties have ever been disclosed.24
• In separate interviews, scientists working to
develop testing technologies for substances
banned in sport state that "they were stymied
by late decisions and a seeming lack of will
at the highest levels of the IOC."25
• It is widely accepted that unannounced, out-
of-competition testing is absolutely
necessary to catch cheaters, yet as of August
14, 2000, two of the 28 international sports
federations (i.e., the International
Gymnastics Federation and the International
Modern Pentathlon Union) had yet to agree
to subject their athletes to out-of-
competition tests in advance of the 2000
Sydney Games.  A third (the International
Volleyball Federation) had "delayed
negotiations so long as to risk the
implementation of a viable out-of-
competition testing program in its sport
before the Olympic Games."26
• In a 30-page deposition filed in July 2000 in
the U.S. District Court in Denver, the former
Director of the USOC's Doping Control
Administration, Dr. Wade Exum, claimed
that the USOC evaded its responsibility to
screen and discipline athletes for drugs in its
quest to produce medal-winners.  He
continued to state in his lawsuit that about
half of the American athletes who have
tested positive for prohibited substances
have gone unpunished.27
...once you start to pull on the thread of this
[doping], the entire garment of the Olympic fabric
begins to come apart....And what you begin to
realize is the IOC itself has nothing to do with
sport.  It has to do with raising money and putting
money in the IOC's coffers and the relationships it
has with its major sponsors....22
--John Leonard
World Swimming Coaches Association (1998)
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In a personal correspondence to The CASA
National Commission on Sports and Substance
Abuse, Dr. Robert O. Voy, Director of the
USOC's Doping Control during the 1980s,
summarized the issues facing the governing
bodies of sports by stating that they have two
strong disincentives to test their athletes
effectively.  The first is financial.  It is extremely
expensive to conduct testing both in and out of
competition.  The high expense is a function of
the necessity to use trained teams capable of
performing unerring collection and processing
and the high cost of laboratory analysis.  Legal
challenges also raise the financial costs of
maintaining a drug-testing program.
The second incentive, according to Voy, is based
on the need for a sports organization to look the
other way regarding what athletes are doing to
enhance performance.  Financial support and the
ability to attract and keep sponsors are based
primarily on a sport's ability to excite and
enthrall an audience.  Should testing become too
effective, sports may suffer because the climb to
set new records may slow or plateau.  Thus, to
the extent that athletes' use of performance-
enhancing substances raises the level of
competition, contributing to the excitement and
enthrallment of audiences, governing bodies
face a conflict of interest in how to deal with
their use.
The IOC is dependent on corporate sponsorship
and broadcast rights for an estimated 75 to 80
percent of its income.29  The balance comes
from supplierships, licensing, ticket revenue and
collectibles (e.g., commemorative coins).  The
IOC itself retains about seven percent of total
marketing revenues which it uses to run the
Olympic movement.  The balance, more than 93
percent, is distributed to:
• The Organizing Committee for an Olympic
Game (OCOG), for administration and
organization costs associated with the
staging of the Games;
• The National Olympic Committees (NOCs),
to help defray their administrative costs,
including that of sending teams to the
Games;
• The 28 Olympic Summer Sports Federations
and the seven Olympic Winter Sports
Federations, to assist in the continuing
promotion of their respective sports; and,
• Various other sports organizations (e.g., the
International Paralympic Committee and the
Paralympic Organizing Committee).
The total value of Olympic marketing revenues
for the quadrennium 1997-2000 is estimated to
be in excess of $3.5 billion.  Top level corporate
sponsors pay an average of $50 million to
sponsor the Olympics for four years.  The top
sponsors are:  Coca-Cola, Eastman Kodak,
VISA, Xerox, Sports Illustrated, Panasonic,
McDonald's, IBM, UPS, John Hancock and
Samsung.  Nine of the top 11 sponsors of the
IOC budget come from the United States.
Coupled with broadcast rights fees, these
companies represent nearly $1 billion in revenue
for the Olympics each year.30  With this much
money at stake, the governing bodies are caught
between their goals of preserving the meaning
and value of sport and promoting sport.  They
have every incentive to minimize the appearance
of doping while, at the same time, hyping the
game and attracting and keeping sponsors.
What's at Stake for Corporate
Sponsors?
Associating products with famous athletes often
increases sales dramatically:
• Wheaties cereal boxes with Lance
Armstrong's image sell about five to 10
percent better than its other boxes
accounting for "millions" of dollars in
The IOC doesn't want sponsors to be unhappy,
and sponsors are unhappy any time their brand
name is tarnished.  That's why the IOC doesn't
want the full extent of doping revealed.28
--John Leonard, Executive Director
American Swimming Coaches Association
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additional sales, according to General Mills
spokesman Tom Johnson.31
• Following the debut of an integrated
marketing campaign (i.e., TV and website)
featuring Marion Jones using Nike shoes,
Mike Wilsky, Nike's Vice President of U.S.
Marketing, was quoted as saying that the
shoe, the Air Cross Trainer II, "immediately
shot to No. 1 in sales," outselling the second
most-popular shoe by a 10-to-1 margin.32
• Bicycle manufacturer Trek splashed Lance
Armstrong's name across its most expensive
bicycle line--bikes that sell for up to $4,000
each--and sales more than doubled, says
company President John Burke.33
• According to Senior Vice President Gail
Sonnenberg, the U.S. Postal Service has
snatched "millions and millions" of dollars
worth of new business from rivals
specifically because of its association with
Lance Armstrong and sponsorship of the 19-
member U.S. national cycling team.34
The incredible popularity of sports creates
enormous marketing opportunities for
corporations with television viewing audiences.
Corporate sponsors spend millions of dollars in
television advertising to leverage their
sponsorships.
• Television companies in the United States
paid $793 million for the broadcasting rights
to the Sydney 2000 Olympic games.  They
have agreed to pay $2.3 billion for the
broadcast rights for the 2004, 2006, and
2008 games.  By comparison, U.S.
broadcasting companies paid $400,000 for
the broadcast rights to the 1960 Rome
games and $401 million for the 1992
games.35
• European broadcasting companies,
negotiating through the European
Broadcasting Union (EBU), agreed to pay
$350 million (US$) for the television rights
to the Sydney 2000 games.  By comparison,
they paid $670,000 (US$) for the rights to
the 1960 games in Rome, $1.7 million
(US$) for the 1972 rights, $19 million (US$)
in 1984, and $90 million (US$) for the rights
to the Barcelona games in 1992.36
With the potential for profit so high,
corporations exploit the public love of sports and
of the winners in order to sell their products.
The corporate goal is to heighten public interest
in sporting events, promote the drive to compete,
revere the winner, associate the winner with
their products and cash in on the profits.
What's at Stake for Society and
Our Children?
Because of the mutually reinforcing
relationships among sports, the family,
education, the economy, politics and religion,
the impact and reach of sports in our society
cannot be overstated.  It is through these
relationships that sports, in a very positive way,
can help promote character building, discipline,
competition, physical fitness, mental fitness,
religiosity and nationalism--both on and off the
playing field.38  These relationships are
reciprocal, however, and the negative aspects of
sport (e.g., doping and the values and messages
associated with this practice) can affect these
other social institutions as well by undermining
them and the values they hope to instill.  Doping
distorts the meaning of sport in society.  It sends
messages to our children that contradict the
values we hope sports participation will evoke.
Everybody wants to know what I'm on.
What am I on?  I'm on my bike...six hours
a day.  What are you on?
--Lance Armstrong, two-time Tour de
France champion in 30-second Nike ad
NBC expects to make a small profit from the
Sydney Games.  It is also looking to the event
to boost its cable networks and attract a big
audience to its fall lineup.37
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To the extent that our athletes are role models
for our children, doping practices compromise
our children's health and safety.
The Meaning of Sport
The Olympic Games have meaning that is well
understood by competitors and spectators alike.
Victory should go to the athlete with the best
combination of natural ability, stamina, courage,
strategic cunning and willingness to undergo
intense and difficult training.39  We admire great
athletes for their strength, speed, skill,
persistence, teamwork and whatever other forms
of excellence that a particular sport allows them
to reveal.40  It is this excellence that gives
meaning to individual athletic performances and
to sports as a whole.
The Olympic Creed makes explicit the meaning
of the Olympics by stating, "The most important
thing in the Olympic Games is not to win but to
take part, just as the most important thing in life
is not the triumph but the struggle.  The essential
thing is not to have conquered but to have fought
well."41  In the face of these principles, doping
by athletes grotesquely twists the meaning,
essence and core values of sport and its practice
undermines the legitimacy of any competition.
Doping threatens the integrity of sport itself and
all the potential benefits sports offer society,
particularly its utility as a means of expressing
and mirroring important social values.
Because athletes are permitted to use many
forms of performance enhancement other than
doping, some argue that anti-doping rules are
arbitrary.  To a significant degree, the rules in
sports are indeed arbitrary, but they are in no
way trivial.42  The size of the playing field, the
height of the net, or the number of players on a
team are all artificially determined by the rules
of the game.  These rules create the structure in
which athletes compete and, in doing so, help
impart meaning to athletic performances.
Toward that end, all Olympic athletes take an
oath to "...take part in these Olympic games,
respecting and abiding by the rules that govern
them, in the true spirit of sportsmanship...."43  As
former Olympic athlete Dr. Angela Schneider
stated in testimony before The CASA National
Commission on Sports and Substance Abuse:
"If you don't have fair play, you cannot have
sport.  Games are arbitrary; we throw together
rules....If we don't stick to these arbitrary rules,
we don't have a game..."44  Fair competition
presumes that the participants will follow all the
rules, including those established in regards to
doping.
Within the sports context, athletes are using
these substances to achieve superhuman feats.
Dr. Schneider further stated:  "What has been
happening in sport is that the technological
advancements cut against our humanity....They
treat the athlete like a piece of meat--like a
performance machine."45  Dr. Thomas H.
Murray, a pre-eminent bioethicist from The
Hastings Center, similarly argued that doping is
a telling manifestation of the dehumanization of
sport:  "If everyone were allowed to use
performance-enhancing substances, then
everyone would be on a level playing field.
Fairness would be accommodated, but such an
allowance would detract from the meaning of
sport.  Sport should be about the pursuit of
excellence and fairness but that pursuit should
not be unlimited or unconstrained.  We are, after
all, human.  Prohibiting the use of performance-
enhancing drugs is an effort to preserve the
meaning of athletic competition."46
Dr. Jay J. Coakley (a foremost expert in sports
sociology), testifying before the Commission,
described the phenomenon of overconformity to
a sport ethic that entails making sacrifices for
the game, striving for distinction, playing
through pain and fighting through limits, even to
the point of risking their safety and well-being
as one of "positive deviance.  "Coaches, trainers,
and parents who subscribe to this positive
deviance (either directly or tacitly) may even use
their substantial influence to encourage the use
of unhealthy and unfair practices, including the
use of performance-enhancing substances.
According to Coakley, " 'positive deviance' is
not a 'positive' in a behavioral or health sense; in
fact, it is dangerous to all athletes."47  Even
beyond just following the rules, doping cuts at
the heart of what is meaningful about sport on a
humanistic level.
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Olympic Athletes as Role Models
A 1999 survey by The Kaiser Family
Foundation found that famous athletes are the
second most admired group of people by youth
(parents are the most admired), coming in ahead
of teachers and friends.  Seventy-three percent
of surveyed youth "look up to and want to be
like" some famous athletes.  Athletes are more
admired than other famous celebrities like
TV/movie stars (56 percent) or musicians/band
members (32 percent).49  These findings suggest
that admiration by youth is not simply about
fame and recognition, but also about heroic
performers and the allure of winners.
Children claim that they gain motivation by
following famous athletes.  The Kaiser study
revealed that by following famous athletes, 96
percent of children learned that excelling in
sports takes hard work and dedication while 54
percent have been encouraged to work harder at
their own sport.  Children also see the negative
aspects of athletes.  In fact, 52 percent think that
it is common to see famous athletes using
steroids or other banned substances to get an
edge on the competition. Of the boys surveyed,
35 percent had heard "a lot" and an additional 30
percent had heard "some" about Major League
Baseball player Mark McGwire's use of
androstenedione.  Twenty-one percent of
respondents had tried to change their body
because of a famous athlete, either by slimming
down or bulking up; five percent of the total
respondents had tried to accomplish this by
using a dietary supplement.50
The Canadian Centre for Drug-Free Sport
(CCDS) conducted a survey in 1992 of high
school and elementary students of knowledge,
attitudes and behavior toward performance-
enhancing substances.  This survey found that of
the students who use anabolic steroids, 53.9
percent use them to do better in sports while
47.2 percent report using steroids to change their
physical appearance.51
Watching role models who are athletes use
performance-enhancing drugs sends strong
negative messages to our children.  A former
Olympic athlete testifying before the
Commission observed:  "Respect for the game
entails respect for your opponents....  The culture
in sport right now is totally antithetical to that.
It is a culture that tries to pull down opponents
using whatever means possible.  It is not
respectful to officials and it's not respectful to
opponents.  We've lost what used to be called
etiquette.  But it's not just about etiquette, it's
about fundamental ethics and fundamental
respect."53
In addition to the values we impart to our
children, what is at stake is their health.  The
"win at any cost" mentality may be mimicked by
younger athletes through the ingestion of
potentially harmful and dangerous substances.
A case in point is creatine--a popular dietary
supplement.  Creatine gained popularity
following the 1992 Summer Olympics when
several medalists admitted to using it, including
Linford Christie and Colin Jackson.  The
problem with young adults trying to emulate
these athletes is that the long-term effects of
creatine (as many other performance-enhancing
substances) are not known and the potential
damage to growing bodies may be greater than
in adults.  Since creatine is considered a dietary
supplement, it is not regulated by the Food and
Drug Administration (FDA).  Therefore, the
purity and quality of creatine on store shelves
vary.
The reason we are involved in this is the 52
million American children.48
--White House drug czar, Barry McCaffrey,
at the IOC Doping Conference
More than a half million 8th- and 10th-grade
students are now using these dangerous drugs
[steroids], and increasing numbers of high
school seniors say they don't believe the
drugs are risky.52
--Alan I. Leshner, M.D., Director
National Institute on Drug Abuse
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Because creatine and other performance-
enhancing substances are classified by the
Federal Government as dietary supplements,
they are viewed as safe.  In the name of health
and fitness, adults and youth are consuming
growing quantities of substances.  According to
one report, over 56 percent of the U.S. adult
population uses some form of vitamins,
supplements or minerals.54  Sports nutrition
appears to be the rising wave in the nutritional
supplements field.  In the past, this category was
perceived mainly as a niche sector dominated at
the retail level by health food specialty stores.
At present, large quantities of these substances
are readily available for purchase anywhere.  For
example, one need only go to the vitamin section
of a local wholesale club (e.g., Wal-Mart) to
purchase a two-pound container of creatine or
other similar products.
Whole new methods of marketing, research and
distribution have arisen to cash in on the sports
and performance enhancement industry.
Manufacturers and distributors of dietary
supplements no longer sell their products only
through retail stores but also advertise heavily
on the Internet and in specialty magazines.
These specialty magazines promote these
products in the name of health and fitness, all to
the tune of millions in profits.  Nutrition stores
display extensive arrays of dietary supplements
with performance-enhancing claims.
• General Nutrition Companies, Inc. (GNC),
which has 4,203 stores in all 50 U.S. states
and 25 foreign markets, had 1998 profits of
$90 million on sales of $1.4 billion.  It has
formed alliances with Rite Aid Corp. drug
stores and Internet retailer Drugstore.com,
Inc.57
• Experimental & Applied Sciences, Inc., a
Colorado-based manufacturer of
performance-enhancing supplements that
enjoys a high profile among professional
athletes, reported annual sales of more than
$150 million.58
Not only are we looking the other way when it
comes to performance-enhancing substances and
youth, we are marketing these products to them
directly.  Even substances that may not be
damaging in a fully developed athlete may have
serious consequences for a child or teen who is
still growing.
The sports nutrition market is worth $1.4
billion a year and is expanding at a rate of
22 percent.55
--Brent Scott, Vice President of Sales
Experimental & Applied Sciences, Inc.
In 1996 the American public purchased 1.2
million kilograms of creatine.  By 1998
consumption had risen to nearly 4 million
kilograms....with personal endorsements from
stars like the Baltimore Orioles' Brady Anderson
and Denver Broncos' John Elway, interest in
creatine is unlikely to wane.56
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Chapter III
The Pharmacology of Competition
Athletes are playing a dangerous game when
they use performance-enhancing substances to
gain competitive advantage.  Many of the
substances they use produce adverse health
effects; for others the effects are still unknown.
Performance-enhancing substances are:  any
substance, either natural or synthetic, foodstuff
or supplement, legal or illegal, that when
introduced into the human body gives the user a
competitive advantage, i.e., allows one to
perform at a level beyond one's natural abilities.
The CASA National Commission on Sports and
Substance Abuse has identified the performance-
enhancing drugs currently used in sports, the
reasons why athletes may use them, the known
side effects of these substances and the current
state of technologies available to detect them.
We also have identified nonperformance-
enhancing drugs banned in Olympic
competition, dietary supplements that may be
performance-enhancing and agents used to mask
or beat a drug test.
Performance-Enhancing Drugs
Anabolic Steroids
The anabolic steroids used by athletes are
synthetic derivatives of the male sex hormone
testosterone.  Testosterone is responsible for the
development of primary male sexual
characteristics.  Anabolic steroids are
distinguished from the corticosteroids, such as
cortisone which break down tissue.
Biochemical/Physiological Effects.  Anabolic
steroids act by binding to specific receptors
A society's recreation is charged with moral
significance.  Sport - and a society that takes it
seriously - would be debased if it did not strictly
forbid things that blur the distinction between the
triumph of character and the triumph of chemistry.
--George Will
October 1988
®
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inside a cell to enhance or inhibit the expression
of specific genes.1  Female use of anabolic
steroids results in development of male
secondary sex characteristics.2  Males who use
these drugs not only become stronger, but may
develop acne and/or abnormal breast tissue.3  In
adolescents, anabolic steroid use promotes an
initial acceleration in skeletal and muscular
growth; however, premature closure of the long
bone growth centers may eventually stunt the
user's growth.4
Therapeutic Uses.  Therapeutic uses of anabolic
steroids include testosterone replacement for
men because of disease, surgery, radiation or
trauma and treatment of a rare hereditary
disorder.5  Anabolic steroids have been found to
help HIV-positive patients with AIDS wasting
syndrome regain body weight, muscle strength
and lean body mass.6  Testosterone replacement
therapy is being tested in aging men to combat
the natural decrease in testosterone that occurs
with aging and thereby restore muscle strength,
muscle mass and bone mass.7
Effects on Athletic Performance.  Athletes use
anabolic steroids to achieve increases in muscle
mass and strength and/or to improve recovery
from training by decreasing tissue breakdown.8
Numerous studies have addressed the issue of
the effect of anabolic steroids on bulk and
strength.  While earlier research was not
definitive,9 several recent studies have
concluded that steroid users do become stronger
and gain size.10
The standard used for assessing the efficacy of
anabolic steroids has been their effect on an
athlete's ability to increase the maximum weight
lifted in a single repetition of a lifting exercise.
How this benchmark correlates with actual
performance in a variety of competitive sports
(other than weightlifting) remains highly
speculative.  Little data are available regarding
the effects of anabolic steroids on motor
coordination and reaction time.
Athletes often use anabolic agents at doses much
higher than prescribed for therapeutic
purposes.11  Due to potential harmful side effects
of steroid use at excessively high dosage levels,
clinical studies, in the past, examined their
effects on athletic performance at relatively low
dosage levels and the results were equivocal.12
However, a 1996 found that high doses of
testosterone, especially when combined with
strength training, increase fat-free mass and
muscle size and strength in normal men.13
Several case studies have documented
aggressive behavior following steroid use and
many other studies have found that steroid users
report feeling more aggressive.14  Other studies
have found no behavioral changes at all due to
steroid use.15
Dosage, diet, training and the type and duration
of anabolic steroid used are all known
confounding variables when attempting to
determine significant differences in anabolic
steroid effects.16
Potential Adverse Effects.  Adverse effects of
steroid use include: liver function abnormalities,
liver tumors, testicular atrophy, development of
abnormal breast tissue in males, masculinizing
effects in females (increased body hair,
deepening of voice), decreased "good
cholesterol" and increased "bad cholesterol."17
Behavioral changes, psychiatric disorders and
drug dependence may occur.18  Injection users
may run a higher risk of infectious diseases
(specifically hepatitis B, hepatitis C and HIV
infection) by sharing contaminated needles.19
Testing.  Classically, anabolic steroids have
been detected using a technique known as gas
chromatographic mass spectrometry (GC/MS).20
This technique is the most reliable and valid
means generally accepted for the accurate
detection of anabolic steroids in the urine.
Recently, technological advances using the more
sensitive high-resolution mass spectrometry
(HRMS) have enabled the detection of the
substances at much lower concentrations.
HRMS was introduced at the Atlanta Games.  Its
newness, however, led to the discarding of test
results over concerns regarding the legal
defensibility of the findings.  With time and
refinement, this technology is expected to
become the gold standard for detecting steroid
and other drug abuse.21
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A more complex problem is that of
distinguishing between testosterone in the urine
that is present normally and testosterone that is
administered by injection, patch, cream or gel.
The current test is predicated upon the biological
observation that normally for every molecule of
testosterone (T) produced in the body there is an
expected amount of the related epitestosterone
(E) also produced.22  Most individuals produce
in their urine one molecule of T for every
molecule of E, resulting in a ratio (T/E) of
approximately 1.23  Because of genetic
variations, some individuals normally have
ratios as high as 6:1.24  Until such time as a more
acceptable method for distinguishing natural
testosterone from self-administered testosterone,
an elevated T/E ratio is used as a marker of
abuse.25
There are several problems associated with this
approach.  For example, nearly eight in 1,000
individuals normally have a T/E ratio greater
than 6:1.26  Second, there is no peer-reviewed
literature validating this ratio in women,
particularly in relation to the menstrual cycle
and use of birth control pills.  This point has
been the subject of much litigation.  Third, self-
administering both testosterone and
epitestosterone allows individuals to dope but
still keep their T/E ratio below 6:1.  Promising
studies are under way to develop the means to
distinguish between natural testosterone and
synthetic testosterone by analyzing the carbon
isotope of each of these substances.27
Further complicating the testing for steroids is
the realization that an abnormal finding in the
urine does not equate always with self-
administration of a banned substance.  For
example, sabotage, i.e., spiking another
competitor's food or drink with a banned
substance, can produce a positive urine result.
While athletes have claimed to be victims of
such sabotage, there are no data documenting
how frequently it occurs.
Some steroid users may attempt to avoid
detection by using a drug called Probenecid.  In
animal studies, this substance has been shown to
interfere with the excretion of some steroids.28
Since anabolic steroids are training drugs, they
are not typically taken during competition, the
only meaningful test for steroid abuse is year-
round, out-of-competition, unannounced testing.
The associated costs and logistical problems are
significant.  In-competition athletic drug tests
currently cost $300 to $500 per test.  At the 2002
Winter Olympics, officials estimate that analysis
of each urine sample will cost $700 to $1000
exclusive of any testing for peptide hormones
(i.e., hGH, IGF-1, EPO) and that $3 million will
be spent on urine collection, transportation and
analysis for less than 1,000 samples.29  Out-of-
competition testing raises these already high
costs appreciably.
The recent spate of positive tests for the steroid
nandrolone underscores how complex the
subject of steroid testing has become.30
Nandrolone can appear in abnormal quantities in
the urine as a consequence of Deca-Durabolin
abuse or as a consequence of the metabolism of
the dietary supplement, 19-norandro-
stenedione.31  Deca-Durabolin is an injected
anabolic steroid and controlled substance which,
if used, indicates unequivocal intent to gain an
unfair competitive advantage.  19-
norandrostenedione is a dietary supplement that
can be taken with intent or unknowingly in a
mislabeled bottle bought over-the-counter.  This
raises the question of how to distinguish use
with regard to intent in the case of a positive test
result.
Stimulants
Stimulants increase alertness, reduce fatigue
and, therefore, may increase competitiveness.
They include the amphetamines, the
sympathomimetic amines (e.g.,
pseudoephedrine), cocaine and caffeine.  These
drugs all produce the telltale signs of
nervousness, irritability, insomnia, palpitations,
weight loss and mild hypertension.  In 1970,
amphetamines accounted for 14 percent of all
psychoactive drugs prescribed by physicians in
the United States, often for weight control.32
The widespread abuse of these drugs, including
in professional sports, led to the passage of the
Controlled Substances Act of 1970 (CSA).33  It
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was soon discovered, however, that the
sympathomimetic amines (which are not
covered by the Controlled Substances Act) when
combined with caffeine mimic the effects of
amphetamine.34  Such combinations became
known as the "look-alikes" and allowed athletes
to circumvent the intent of the CSA.  The
ubiquity of these drugs has presented particular
problems in the world of sports, especially since
each component of the "look-alikes" can be
readily obtained and mixed.
Amphetamines
Biochemical/Physiological Effects.
Amphetamines elevate blood pressure and
initially slow the heart rate. Amphetamine use
causes wakefulness, alertness, decreased sense
of fatigue, elevation of mood, increased
initiative and self-confidence, an increase in
motor and speech activity and a decreased
appetite.35  Tolerance to these effects occurs
with repetitive use, leading to continued
increases in the dosage of amphetamines in an
attempt to achieve the same effect.36
Therapeutic Uses.  The legitimate therapeutic
use of amphetamines has become increasingly
narrow.  They are used for childhood
hyperactivity, attention deficit disorder, as an
adjunct in chronic pain patients taking opiates,
and for certain central nervous system diseases
(e.g., narcolepsy) to overcome
drowsiness/sleepiness.37
Effects on Athletic Performance.  The
amphetamines became popular with athletes
because of their ability to delay the onset of
fatigue during intense exercise, to reduce weight
and to increase concentration.  A landmark study
done in 1959 demonstrated enhanced
performance in 75 percent of the runners,
swimmers and throwers taking amphetamines.38
Since then, available evidence suggests that
amphetamine use can enhance athletic
performance, including speed, power,
endurance, concentration and fine motor
coordination.39
Potential Adverse Effects.  Amphetamines
produce acute effects such as restlessness,
irritability, insomnia, headache, palpitations and
anorexia.  An irregular heartbeat or palpitations
may result with abuse.  Severe effects can
include confusion, hallucinations, convulsions,
cerebral hemorrhage, heart attack and
circulatory collapse.  Addiction and weight loss
can result from chronic abuse.40
Testing.  Amphetamines are absorbed rapidly
into the circulation, with blood levels peaking in
one to two hours.    The clinical effects can
appear within half an hour and can last in excess
of three hours.41  Although the amphetamines
are readily detectable in urine, laboratory testing
is complicated by the close chemical similarity
to sympathomimetic amines.  Laboratory testing
may have to include testing for the different
forms of amphetamine and methamphetamine to
insure accuracy of drug identification.
Amphetamines are "time of event" drugs used at
the time of competition rather than drugs used
during the time of training for athletic
performance enhancement.  Out-of-competition
testing for these drugs is therefore less relevant.
The period of detection of amphetamines in
urine by GC/MS is up to five days after last
use.42  Testing for amphetamines is covered in
the average cost of an in-competition test (i.e.,
$300-500 per test).  This type of screening also
can detect Ecstacy, a popular amphetamine-like
designer drug.  Other designer drugs that
function as stimulants are constantly being
developed, challenging the ability of testing to
keep pace.
Sympathomimetic Amines
Biochemical/Physiological Effects.  Similar to
amphetamines, these drugs raise blood
pressure,43 increase the heart rate and dilate the
air passages in the lungs.44  High doses may be
associated with euphoria and increased
alertness.45
Therapeutic Uses.  The sympathomimetic
amines are widely available as over-the-counter
(OTC) cold remedies.  They are also used to
treat seasonal allergies and related respiratory
disorders.  Ephedrine, in years past, was widely
used in the treatment of asthma.
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Phenylpropanolamine is a common ingredient in
diet pills.
Effects on Athletic Performance.  These drugs
are believed, by many athletes to produce effects
similar to those of amphetamines.  Ephedrine
use by swimmer Rick DeMont in 1972 caused
the first United States Gold Medal to be
forfeited in Olympic competition.46  There is a
lack of scientific documentation, however, of
actual enhancement of performance directly
related to the use of these drugs as stimulants.  A
common use for ephedrine, when used in
combination with caffeine, is to decrease body
weight and thereby enhance performance.47
Potential Adverse Effects.  Sympathomimetic
amines produce side effects similar to
amphetamines, including nervousness,
irritability, dizziness, palpitations and mild
hypertension.  Severe effects can include
agitation, confusion, hallucinations, stroke,
cerebral hemorrhage and severe hypertension.48
Testing.  The sympathomimetic amines are
detectable in urine with the same methods and
detection windows relevant to amphetamines.  In
an attempt to separate legitimate therapeutic use
(e.g., medication for upper respiratory infection
with an OTC decongestant) from abuse, the IOC
and the International Federations raised the
tolerance levels for the sympathomimetic
amines.
Cocaine
Biochemical/Physiological Effects.  Cocaine is
derived from the leaf of the coca plant.  Cocaine
hydrochloride is the form of cocaine that is
either inhaled or injected.  Free base cocaine and
"crack" decompose at a higher temperature and
thus are smoked.  Cocaine use produces
constriction of blood vessels, increased heart
rate, dilated pupils and increased body
temperature.  Its effects also include increased
alertness and energy, decreased fatigue,
increased sense of well-being, loquaciousness,
repetitive behaviors, loss of appetite and intense
euphoria.49  These effects are brief and generally
last less than 30 minutes.50  Cocaine increases
concentrations of certain neurotransmitters such
as dopamine which is responsible for much of
the euphoric effect.51  The potent "high" of
cocaine accounts for its frequent repetitive
dosing among users.
Therapeutic Uses.  Cocaine, usually in
combination with epinephrine, is widely used as
a topical anesthetic for nasal surgical
procedures.
Effects on Athletic Performance.  Despite the
amphetamine-like properties of cocaine, no
evidence suggests that cocaine enhances athletic
performance in a sustained fashion given its
short duration of action.  Performance
deteriorated by fatigue could be briefly restored
to normal but frequent use would be necessary
to sustain it.52  Athletes' use of cocaine--an illicit
drug of abuse--is primarily for purposes other
then performance enhancement
Potential Adverse Effects.  The acute effects of
cocaine use may include insomnia, euphoria and
depression, confusion, delirium, paranoia,
hallucinations, psychosis, repetitive behavior
and anorexia and addiction.53  Convulsions,
seizures and other neurologic complications may
occur54 and the risk of sudden death as a result
of a heart attack or irregular heartbeat is
increased.
Testing.  Urine, blood and hair tests may be
used to detect cocaine.  The period of detection
in urine is up to five days following last use,
depending on dose and duration of ingestion.55
Caffeine
Caffeine is one of the most widely used drugs in
the United States and around the world.  Its use
dates back to Paleolithic times.  It is commonly
found in coffee, tea, chocolate products, diet
pills and in a wide array of over the counter
drugs including Excedrin, Dexatrim and No
Doz.
Biochemical/Physiological Effects.  Caffeine is
a central nervous system stimulant.  The main
psychic effects following caffeine ingestion
include increased alertness, clearer thinking,
shortened reaction time and increased capacity
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for attention-requiring tasks.56  Caffeine is
readily absorbed following ingestion.  Caffeine's
effects can be perceived as performance-
enhancing when taken in excess.
Therapeutic Uses.  Caffeine is used
therapeutically for headaches when taken in
moderation.
Effects on Athletic Performance.  Believing
that it will enhance performance, athletes have
long consumed caffeine both alone and in
combination with the sympathomimetic amines.
Whether caffeine has a significant enhancing
effect on high-intensity, short-term exercise is
questionable.57  There is better evidence for its
enhancing effect on endurance performance
through its wide-ranging physiological and
psychological effects.58
Regarding caffeine's effect on other measures of
performance that are important in athletic
competition, the data tend to be poorly
substantiated and/or contradictory.  For example,
some studies indicated that ingesting caffeine
does not produce less drowsiness, increased
vigilance, reduced fatigue and/or an increased
capacity for sustained intellectual work.  Other
studies show that performance on mental tasks
which require prolonged concentration is
significantly improved after caffeine ingestion.
Still other reports state that coordination and
other fine motor skills are neither clearly
enhanced nor diminished following caffeine
ingestion.59
Potential Adverse Effects.  The effects of
chronic caffeine intake include nervousness,
irritability and insomnia and may occur in
different individuals at varying doses.  Effects of
acute use include: rapid heartbeat,
gastrointestinal distress, peptic ulcer, severe
hypertension, delirium, seizures, coma,
arrhythmia and even death.60  At the threshold at
which performance is enhanced (about 400 mg),
few adverse health effects would be noted.
Extremely high doses of caffeine are not needed
to improve performance since there does not
seem to be a dose-response relationship between
caffeine (beyond a threshold) and endurance
performance.61
Testing.  Caffeine is detectable readily in urine.
To test positive for caffeine use requires
ingesting the equivalent of six to eight cups of
coffee in one sitting and testing within two to
three hours.62
Beta-2 Agonists
Biochemical/Physiological Effects.  Beta-2
agonists are unusual because they are classified
by the IOC as both stimulants and as anabolic
agents.  Several animal studies have found that
beta-2 agonists significantly reduce the amount
of body fat by up to 20 percent.63  They have a
fat reducing effect in humans too, but most
likely not to the same extent as in animals
because there is no evidence humans can tolerate
the comparative doses that were given in the
animal studies.  There are large variations in the
duration of action of the beta-2 agonists,
depending upon the specific drug, its dose,
and/or the route of administration.
Therapeutic Uses.  Beta-2 agonists such as
salbutamol, salmeterol and terbutaline are
permitted "in the aerosol or inhalant forms only
to prevent and/or treat asthma and exercise-
induced asthma."64  These drugs are nearly 95
percent effective in protecting against exercise-
induced asthma and have long been first-line
therapy for this purpose.65
Effects on Athletic Performance.  There is no
research documenting that the inhaled beta-2
agonists enhance athletic performance in
individuals who do not suffer from exercise-
induced asthma.66  However, there is little
question that they do enhance performance in
individuals with such disorders.  When beta-2
agonists are taken either orally or by injection,
there have been documented performance-
enhancing effects.67  Examples of beta-2
agonists that are prohibited even in the inhaled
form include clenbuterol and reproterol.68  One
form of beta-2 agonist, clenbuterol, was the drug
that tainted the 1992 Barcelona Olympics.
Potential Adverse Effects.  Leading side effects
include rapid and irregular heartbeat and muscle
tremors.69
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Testing.  There is no simple test for beta-2-
agonists.  Screening for beta-2-agonists is
performed by gas chromatography, with
confirmation analysis performed by GC/MS.
Screening analysis for clenbuterol is commonly
accomplished by inclusion in the anabolic
steroid GC/MS screening procedure.  The period
of detection of beta-2-agonists in urine is up to
five days after last use.70  A positive test result
for beta-2 agonists does not distinguish whether
the intent of use was for therapeutic or
performance-enhancing reasons.  Thus, testing
for beta-2 agonists poses a more serious problem
for officials in terms of determining intent,
positive test result management and sanctions.
The cost of testing ranges from $300 to $500,
similar to tests for amphetamines.71
Beta-Blockers
Biochemical/Physiological Effects.  Beta-
blockers refers to a class of drugs that block the
action of adrenaline (by blocking the beta-
adrenergic receptors) and thereby relieve stress
to the heart muscle.72
Therapeutic Uses.  Beta-blockers are often used
to slow the heart rate or lower the blood
pressure.  They commonly are used in the
treatment of hypertension, angina and certain
heart beat irregularities, and they serve as
primary treatment for migraine relief and for
control of tremors.73
Effects on Athletic Performance.  Beta-
blockers are used by athletes who compete in
events that require hand and arm steadiness,
such as archery, pistol shooting and riflery due
to their anti-tremor and anti-anxiety effects.74
Potential Adverse Effects.  Reduced
functioning of the heart and congestive heart
failure may develop in individuals with pre-
existing heart problems.  These drugs may
induce bronchospasms in asthmatics, or may
cause insomnia, nightmares and depression.
Sexual dysfunction may develop in males who
use beta-blockers.75
Testing.  Beta-blockers are time-of-competition
drugs.  The level of drug in the urine is
determined using GC/MS.76
Human Growth Hormones (hGH)
Biochemical/Physiological Effects.  Growth
hormone is a peptide hormone secreted by the
pituitary gland.  A major function of hGH is the
maintenance of normal rates of growth from
birth until the attainment of adult height.  Its
most apparent effects occur during adolescence.
The release of hGH is controlled by many
factors including diet, exercise, nutrition, drugs
and various biological feedback mechanisms.
High-intensity exercise is associated with an
elevation in growth hormone levels.77
Therapeutic Uses.  In the United States, two
genetically engineered human growth hormone
products have been approved by the FDA;
somatropin and somatrem.  These drugs are
restricted to people with documented growth
hormone deficiency (short stature, Turner's
syndrome and delayed puberty).  hGH has been
shown to be effective in increasing weight,
increasing lean body mass and improving
muscle power in HIV-positive patients with
AIDS or AIDS-complex.78
Effects on Athletic Performance.  Growth
hormone appeals to athletes who are trying
increase their lean body mass and shorten
recovery time.79  The fat-burning properties of
hGH are documented80 and studies have also
shown increases in fat-free weight.81  In one
study, however, hGH had no effect on highly
trained power athletes with little fat mass and
high lean body mass suggesting that a ceiling
may exist for the desirable effects of hGH.82
Athletes may use hGH believing that it shortens
recovery time although this finding is
unsubstantiated.  To date, there are no well-
controlled studies of hGH demonstrating actual
improvements in strength or endurance as a
consequence of its use in nongrowth hormone
deficient individuals.  Although there may be an
increase in muscle size, there is no evidence of
any increase in muscle strength.  Anecdotal
evidence suggests that many athletes think that
hGH use will give them the same sought-after
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effects of steroids without the risk of the drug
being detected or of the same adverse effects
associated with steroid use.83
Some parents and adolescents believe that they
can increase artificially an adolescent's height by
taking growth hormone, although there is no
objective evidence to substantiate the belief.
Because it does not produce the same
masculizing effects of anabolic steroids, hGH
has potentially more appeal to females than
steroids.
Potential Adverse Effects.  Side effects that
have been reported include headache,
enlargement of the adenoids with snoring and
further growth of the hands, feet and face.
Enlargement of the internal organs--heart, liver,
spleen and kidneys--may occur.84  Other effects
include disorders of the peripheral nerves,
diabetes, hypertension, premature cardiovascular
disease, impotence, osteoporosis and colonic
polyps.85  As with all abused injectable drugs,
there is a risk of acquiring HIV, hepatitis and
bacterial infections if contaminated needles are
shared.
Testing.  Currently, there is no reliable and valid
test to detect the abuse of hGH.  As with
anabolic steroids, it is used as a training drug
and will require that testing be done on a year-
round, out-of-competition, unannounced basis.
Insulin-like Growth Factor (IGF-1)
Biochemical/Physiologic Effects.  IGF-1 is a
peptide hormone that is indirectly responsible
for the growth-promoting effects of hGH.86  It
stimulates protein synthesis.87  Independent of
hGH, IGF-1 reduces protein break down and
increases the number of cells.88
Therapeutic Uses.  There are two approved
uses for IGF-1--Larontype dwarfism and type A
insulin resistance syndrome.  In the former, hGH
receptors do not respond to hGH but do respond
to IGF. IGF-1 is currently under investigation
for use against such diseases as advanced AIDS,
osteoporosis and advanced kidney disease.
Effects on Athletic Performance.  There are no
studies demonstrating any performance
enhancement capabilities attributable to IGF-1,
be it gains in strength, aerobic capacity or lean
body mass.  As with growth hormone, there are
no masculizing effects (as seen in the abuse of
steroids) in females.  IGF-1 is banned on the
presumption that the drug's ability to increase
muscle mass allows the potential for unfair
ergogenic gains.
IGF-1 appeals to many of the same individuals
who use hGH.  Like hGH, IGF-1 is injected
intramuscularly.  However, in view of its
newness to the marketplace, very little is known
about its abuse patterns.89
Potential Adverse Effects.  Side effects of IGF-
1 use are similar to those of hGH.  Drops in
blood sugar (hypoglycemia) are common.90  As
with all abused injectable drugs, there is a risk of
acquiring HIV, hepatitis and bacterial infections
if contaminated needles are shared.  Recently,
gene transfer techniques have made it possible to
target the injection of IGF-1 directly into a
muscle, limiting its effects to the injected muscle
and averting systemic side effects.91
Testing.  IGF-1 and the other peptide hormones
(EPO and hGH,) are potentially attractive to
athletes because they cannot be detected through
routine urine drug screening.  Studies of ways to
detect IGF-1 in blood are underway but, as of
yet, there are no reliable and valid tests.  Gene
transfer using IGF-1 also may preclude any
reasonable hope of detecting ergogenic use of
IGF-1 by athletes in the future.
Erythropoietin (EPO)
Biochemical/Physiological Effects.  The rate of
production of red blood cells is, in part,
governed by EPO.  EPO stimulates bone marrow
stem cells to produce red blood cells, which in
turn transport oxygen from the lungs to all
organs of the body, including the muscles.
The duration of the peak benefits of EPO is a
function of the route of administration:  between
four and five hours when administered
intravenously and between five and 24 hours
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when administered subcutaneously.92  Despite its
primarily short term effects, red cell production
is stimulated for as long as three weeks.93
Therapeutic Uses.  The gene that codes for
EPO was cloned in 1985.  As a result, EPO
became clinically available in Europe in 1987
and in the United States in 1989.  Although its
initial clinical use was limited to anemia
associated with chronic kidney disease, its
clinical applications have been expanded and
now include use for treatment of anemia
associated with AIDS and chemotherapy.
Effect on Athletic Performance.  EPO found
its way into sports as an alternative to blood
doping, the practice of intravenously infusing
blood into an individual in order to induce an
elevated red blood cell count.  Blood doping has
been used by athletes in aerobic sports to
increase their total aerobic power by increasing
the transport of oxygen to their working
muscles.  It is a dangerous practice that has long
tainted sports.  Blood doping and EPO
administration both result in enhanced aerobic
power.
Potential Adverse Effects.  The abuse of EPO
raises both the red blood count and the thickness
of the blood, which can simulate the effects of
certain blood diseases and raise the possibility of
clot formation, stroke and heart attack.94  With
dehydration that normally accompanies
endurance sports, there is a further increase in
blood viscosity and a substantially increased risk
of heart attack or stroke.  As with all abused
injectable drugs, there is a risk of acquiring HIV,
hepatitis and bacterial infections if contaminated
needles are shared.
Testing.  The International Cycling Union and
International Ski Federation use a hematocrit
level (red blood cell count) of greater than 50 as
an indicator of EPO abuse.  This is somewhat
problematic in that there are individuals who
normally have hematocrits of greater than 50 for
a variety of reasons.  Genetics plays a role in
determining normal hematocrit levels.  Training
at high altitudes or by using a hypobaric oxygen
chamber can increase EPO and hematocrit levels
as well, without the use of any pharmacological
intervention.95
The International Olympic Committee's medical
commission approved the use of two tests for
EPO on August 1, 2000 for the upcoming
Summer games.96  On August 28, 2000, the IOC
executive board announced that it had approved
plans to carry out EPO testing. Between 300 and
400 out-of-competition tests for EPO will be
conducted randomly in Sydney.97
Although previous urine tests could not detect
the difference between natural and artificial
EPO, the new French test (urine test) can make
this distinction.  It detects direct use of EPO but
only for a period of three days.98  The new
Australian test detects changes in the blood
caused by use of EPO.  Although this is an
indirect test, it can detect use for two to three
weeks.99  Current requirements  for the 2000
Olympics are that both the urine and blood tests
be positive for EPO to avoid false positives.
While this will minimize the possibility of false
positives, it does leave a window open for
athletes to use EPO and avoid sanctions due to
the short detection time of the urine test.
EPO is essentially a training drug and its effects
long outlast its detectability.  Testing for EPO
would have to be done year-round, unannounced
and randomly.  For these reasons, the costs and
logistics associated with such testing may be
quite high.  In addition, testing for EPO would
involve the much more intrusive method of
getting a blood sample.  The blood test for EPO
costs between $600 and $800 while the urine
test for EPO costs $2000.100
Narcotics
Biochemical/Physiological Effects.  This class
of drugs includes opium and its natural and
synthetic derivatives including heroin, morphine
and codeine.  These drugs have primary effects
on the central nervous system and the
gastrointestinal tract.  The effects of narcotics
are pain relief, feelings of either elation or
sedation, drowsiness, mental clouding and
decreased bowel activity.  In higher doses,
muscular rigidity, respiratory depression and
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low blood pressure may occur.  Tolerance to the
drug develops fairly quickly when using opiates,
resulting in the use of higher and higher doses to
obtain the same effects.101  Withdrawal from the
drug once physiological dependence has
occurred results in symptoms including nausea,
vomiting, abdominal cramps and muscle
aches.102  Oral narcotic use has a peak effect
time from one to two hours and a duration of
three to six hours.103
Therapeutic Uses.  Narcotics are used primarily
to manage moderate to severe pain.  They are
also among the best drugs to suppress coughs
and diarrhea.  Methadone is used to wean people
off heroin or maintain them in some cases.
Effects on Athletic Performance.  Narcotics
are frequently used by athletes who are injured
or in pain in order to compete at optimal
performance levels.  This blocking of pain,
which allows the athlete to keep performing, can
lead to severe, even career-ending results.
Narcotics were added to the IOC list of banned
substances for their potential for increasing the
possibility of serious injury to an athlete linked
to playing through pain.
Potential Adverse Effects.  Adverse effects of
narcotics include: nausea, vomiting, dizziness,
mental clouding, sedation, constipation, delirium
and addiction.104
Testing.  Urine, blood, and hair testing may be
used to detect the presence of narcotics.  Tests
for narcotics may include morphine, codeine and
over 20 different synthetic products.  Morphine
detected in urine may be from use of morphine
or may be present as a metabolite of heroin use.
Urine samples containing morphine and codeine,
with the morphine in greater concentration than
codeine, are most likely positive due to the
consumption of poppy seed food products.
Urine samples containing morphine and codeine,
with the codeine in greater concentration than
morphine, are most likely positive due to the use
of pharmaceutical codeine.  Opiates can be
detected in urine for up to five days following
last use.105
Nonperformance-Enhancing Drugs
Alcohol
Despite the tremendous economic and social
costs associated with its abuse, alcohol has the
unique distinction of being the only potent drug
in which self-induced intoxication is widely
accepted.  It is the most abused nonperformance-
enhancing drug in sports.106
Biochemical/Physiological Effects.  Alcohol
(ethanol) is a general central nervous system
depressant.  Once ingested, it is absorbed rapidly
into the blood stream and distributed throughout
the body.  Alcohol's effects can range from
euphoria and giddiness to coma and even death,
depending on blood alcohol concentration.107
Blood alcohol levels are influenced heavily by
body weight and/or the presence of food.
Certain parts of the brain are particularly
susceptible to alcohol's effects, resulting in loss
of  coordination and lessened awareness of pain.
Central nervous system effects are generally
proportional to the concentration of alcohol in
the blood.108  Euphoria, impaired mental status
and a slight loss of coordination occur at lower
levels of alcohol in the blood.  Higher levels
result in nausea, vomiting and marked
clumsiness.  Cold sweat, anesthesia and coma
can occur at still higher levels.109  Variables such
as genetics, nutrition and general state of health,
influence alcohol-related adverse effects.110
Therapeutic Uses.  Ethanol has very limited
clinical use.  It is used as a solvent for the
delivery of many drugs and dehydrated alcohol
can be useful as a nerve block for pain relief in
certain disorders.
Effects on Athletic Performance.  Alcohol is
usually not viewed as a performance-enhancing
drug, although some studies indicate that low-
dose alcohol may reduce anxiety that could
hypothetically improve athletic performance in
certain sports (e.g., riflery).111  Studies
consistently show significant deterioration in
several aspects of psychomotor skills and
performance decreases as blood alcohol levels
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increase.112  Balance and steadiness, reaction
time, fine and complex motor coordination,
visual tracking and information processing are
all impaired as blood alcohol levels increase.113
Alcohol has been shown to increase running
times in sprinting and middle distance events.114
Decreases in anaerobic strength tasks (muscular
output as in the vertical jump) also may occur
following alcohol administration.115  Endurance
(as measured by aerobic capacity), maximum
oxygen uptake and oxygen consumption all
appear to be unaffected by alcohol at small or
moderate quantities.116
Athletes who consume alcohol to the point of
legal intoxication (blood alcohol content of 0.1)
the evening before practice or competition may
subsequently perform significantly worse in
tasks requiring attention and visual-motor
coordination skills for as long as 14 hours.117
Potential Adverse Effects.  Chronic alcohol
consumption may eventually cause tolerance,
addiction and numerous adverse health effects.
Because of the dehydration effects of alcohol,
the use during an athletic event can result in heat
intolerance.118  Individuals dependent on alcohol
may experience alcohol withdrawal syndrome,
including tremors and hallucinations.  Excessive
alcohol consumption can cause damage to the
brain, heart, skin and blood, can damage the
endocrine system, disrupt metabolism and cause
psychiatric and sexual maladies.119
Testing.  Breath, urine and blood tests may be
used to detect alcohol.  The period of detection
of ethyl alcohol in blood, breath or urine is only
a matter of hours after consumption--much
shorter than testing for other abused drugs or
chemicals.  Use of over-the-counter cold
medications containing ethyl alcohol, which
may contain up to 30 percent alcohol, result in
detectable amounts of alcohol in the urine.120
Marijuana
Biochemical/Physiological Effects.  Marijuana
is derived from the leaves and stems of the plant
Cannabis sativa.  It contains over 400 chemical
entities, of which 60 are biologically active.121
The main active ingredient is delta-9-
tetrahydrocannabinol (delta-9-THC).  Numerous
biochemical effects influence behavior.  In
recent years, the potency of some marijuana has
increased five to 10 times or more.122  An
understanding of the pharmacology of illicit
marijuana is complicated by the variations in
dosages used, as well as by the presence of
numerous adulterants, including phencyclidine
(PCP).  Extraction processes produce more
potent forms of marijuana, such as hashish and
hashish oil.
While marijuana can be smoked or taken orally,
the efficiency of the delivery of delta-9-THC is
about 14 percent greater if smoked.123  The
strongest effects occur within 20 to 30 minutes
of smoking marijuana, although effects persist
for between two to four hours.124  If taken orally,
the peak effects occur between 30 minutes and
two hours of ingestion, while effects last from
three to five hours.125
Therapeutic Uses.  Marijuana is not recognized
or approved for medical use in the United States
by federal law, although it is legal for medical
purposes by state law in some states (Arizona,
California, and Washington).126  Smoking as a
pharmaceutical route of administration is not
practiced for any current medication in the US.
Cannabinoids, chemicals unique to the Cannabis
sativa plant, have been isolated and purified and
studied for therapeutic use.  THC has been
approved as a therapeutic agent to control
nausea associated with cancer or AIDS therapy.
For almost all therapeutic applications studied
there are currently adequate alternative
pharmaceutical products available.
Effects on Athletic Performance.  No
performance-enhancing effect has been
attributed to marijuana use, although it does
promote weight gain and relaxation which could
theoretically improve performance in some
sports.127  Many of the acute effects of marijuana
are harmful to athletic performance, such as
impaired eye-hand coordination and reaction
times, and reduced motor coordination, tracking
ability and perpetual accuracy.128  As with
alcohol, marijuana use the night before a
practice or game may impair performance.  The
immediate effects of marijuana may last as long
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as four hours while skill impairment may persist
for as long as 24 hours after marijuana
intoxication.129   Marijuana decreases endurance
and reduces exercise performance.130
Potential Adverse Effects.  Side effects for
marijuana use include paranoia, panic attacks,
delirium, psychoses, decreased attention span
and concentration ability, decreased memory,
euphoria, excitement, calmness, dissociation of
ideas, relaxation, anxiety, distortion of time and
visual perception, and a decrease in
psychomotor performance (nonreflexive
movement).131  Chronic marijuana use is
associated with apathy, impaired judgment, loss
of ambition and an inability to carry out long-
term plans.132  Both psychological and physical
dependence can occur.133  Chronic inhalation of
marijuana may cause damage to the sinuses,
voice box and lungs.134
Testing.  Urine and blood tests may be used to
detect marijuana.  At the IOC screening level, an
occasional or chronic marijuana user may be
detected for up to three days following last
use.135  Detection is complicated by the many
commercial products sold over the internet or at
nutritional/sports supplement stores to "beat the
test."  Some adulterant products (Whizzies,
Klear) may chemically "destroy" the evidence in
the urine.  Another product, Stealth, is reported
to both destroy evidence of the drug and all
traces of itself.136
Dietary Supplements
Nutritional supplements have become popular
components of athletes' strategies to maximize
the results of exercise and weight training.  The
passage of the Dietary Supplement Health and
Education Act (DSHEA) of 1994 was followed
by an enormous increase in the sale of dietary
supplements in the United States and around the
world.  Under the Act, a dietary supplement is
defined as:  "…a product (other than tobacco)
that is intended to supplement the diet that bears
or contains one or more of the following dietary
ingredients:  a vitamin, a mineral, an herb or
other botanical, an amino acid, a dietary
substance for use by man to supplement the diet
by increasing the total daily intake, or a
concentrate, metabolite, constituent, extract, or
combinations of these ingredients."137  The law
prohibits express or implicit claims that a dietary
supplement has an effect on identifiable diseases
or class of diseases.  The law permits the
manufacturer to use structure or function claims
(e.g., increased strength and muscle mass) for its
products without prior FDA approval.* 138
There are countless dietary supplements
currently available.  To name but a few, they
include ephedrine, glutamine, branched-chain
amino acids, creatine, leucine, beta-hydroxy-
beta-methylbutyrate (HMB), chromium, L-
carnitine, choline, vanadyl sulfate, boron,
dehydroepiandrosterone [DHEA] and
androstenedione.  Ephedrine (e.g., Ma Huang) is
used to lose weight and is one of the most
commonly abused dietary supplements.139
DHEA was found to be less effective at
increasing muscle mass and is being marketed
now towards an older population with promises
of looking and feeling younger.  There are
hundreds of other dietary supplements on the
market, even though there is insufficient
evidence on efficacy or adverse effects for many
of them.
At the point of sale, supplements like
androstenedione and DHEA that are precursors
to testosterone, are not controlled substances (as
defined by the Controlled Substances Act),140
but are converted into testosterone (which is a
controlled substance) by the human body where
they exert their hormonal effects.  Thus, some of
these substances pose a unique problem to
sports.
Complicating the testing process is the
incomplete labeling of nutritional products.
Athletes have posed several challenges to
doping accusations on the grounds that
inadequate and inaccurate labeling of nutritional
* Drugs, as distinguished from dietary supplements,
are regulated by the Food and Drug Administration
(FDA). The FDA determines whether drugs are
offered over the counter or by prescription.  Drug
manufacturers are responsible for assuring safety and
purity of the products.
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supplements resulted in their unintentional
ingestion of a banned substance.  Because
nutritional supplements are unregulated and their
labeling not closely monitored, athletes have no
way of truly knowing what is in a nutritional
supplement prior to taking it.  Consequently,
upon a positive test result, two possibilities
present themselves.  Either the athlete is an
innocent victim of circumstance (i.e., the athlete
used what he or she perceived to be a legal
nutritional supplement based on the product
label) or a doping infraction has occurred
wherein the athlete is using the uncertainty of
the supplement's labeling as a convenient
excuse.
Creatine
Biochemical/Physiological Effects.  Creatine
phosphate plays a vital role in regenerating ATP
(an energy storing molecule found in all cells) in
skeletal muscle providing energy for muscle
contraction.141  Creatine supplementation can
increase muscle phosphocreatine content (but
not in all individuals).142  Traces of creatine are
normally present in the urine.  An increase in
muscle creatine content can delay the onset of
fatigue during high-intensity, short duration
muscle work.143  Thus, oral creatine
supplementation has become popular among
athletes and bodybuilders to enhance their short-
term physical performance.
Therapeutic Uses.  Creatine has been shown to
increase strength in patients with neuromuscular
diseases.144  Creatine is used to treat patients
with gyrate atrophy, a progressive disease
affecting the eye.145
Effects on Athletic Performance.  Unlike most
dietary supplements, there is a body of research
demonstrating performance enhancement from
creatine supplementation in exercise (repetitive,
high-intensity, very short duration exercises
associated with short recovery times).146
However, the response is not universal.147  Some
benefit; some do not.  In the short term, most
reports of creatine supplementation have
demonstrated an increase in fat free mass,148
although much of this weight gain may be
related to water retention rather than an increase
in lean body mass.149  Creatine plus weight
training leads to greater increases in strength
than weight training alone.150
Although the IOC does not ban creatine, its use
contravenes the initial intent and definition of
doping which called for the banning "of any
physiologic substances taken in abnormal
quantity for the purpose of enhancing athletic
performance."151
Potential Adverse Effects.  Despite the
incredibly fast growth in the use of creatine in
recent years, reports of side effects have been
relatively few152 and, anecdotally appear to be
related primarily to water retention and muscle
cramps.  Since there are currently no long-term
prospective studies addressing the adverse
effects of creatine supplementation, the negative
long-term effects are unknown.  There is some
evidence to suggest that ingesting creatine
supplements tends to decrease the body's own
natural production of creatine in a variety of
organs including the brain and testes.153
However, once supplementation is stopped,
endogenous creatine levels appear to return to
normal.154
Testing.  Creatine readily appears in the urine as
creatinine.155  Since one can, however, consume
large amounts of creatine in diets rich in meat
and fowl, to date there is no practical way to
establish acceptable cut-off levels for the
purpose of sanctions.
Androstenedione
Biochemical/Physiological Effects.
Androstenedione is a naturally occurring
hormone produced by the adrenal cortex, ovary
and testes.156  It is converted in the liver to
testosterone.157  Androstenedione is considered a
dietary supplement under DSHEA,158 not as a
drug, even though it is classified
pharmacologically as an androgenic (producing
masculine characteristics) steroid.159
Consequently, it can be bought without a
prescription.
Therapeutic Uses.  There are no known
therapeutic uses of androstenedione.
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Effects on Athletic Performance.  Although
use by Major League Baseball player Mark
McGwire brought androstenedione to public
attention, it was developed by the East Germans
in the early 1970s and administered intranasally,
typically before an event, in an attempt to
enhance the performance of their Olympic
athletes.160  The attractiveness of
androstenedione lay in the fact that it
purportedly could provide the athlete with the
advantages of anabolic steroids both legally and
relatively inexpensively.  Despite being legal for
over-the-counter purchase, androstenedione is
banned by some sports organizations,161
although no studies to date have documented
performance-enhancing effects.  A 1999 study
found that oral androstenedione supplementation
(300 mg per day) does not increase testosterone
concentrations nor does it provide any
advantages during strength training.162
However, a more recent study suggests that oral
androstenedione (when given in dosages of 300
mg per day) increases serum testosterone and
estradiol concentrations in some healthy men.163
This may result in the same competitive
advantage as taking testosterone.
Potential Adverse Effects.  Androstenedione is
metabolized to testosterone and to estrogens,
including estradiol, a female hormone with
known side effects (e.g., breast enlargement in
males).164  Although not adequately studied, the
abuse of androstenedione and related substances
may result in similar adverse effects associated
with the abuse of anabolic steroids.165  As with
anabolic steroids, these adverse effects may
include testicular atrophy, and masculinization
in females.166  In a 1996 study, androstenedione
was associated with a decrease in HDL, also
known as "good cholesterol."167  Exposure to
elevated levels of estradiol in women may
increase their risk for breast cancer.168  Since
DSHEA does not require the manufacturer to
prove purity, samplings of marketplace
supplements have revealed commercial products
with varying levels of androstenedione--from
very high to none at all, while some actually
contain the male hormone testosterone.169
Testing.  Androstenedione is detectable in urine.
Because androstenedione is converted to
testosterone, its use has been demonstrated to
produce T/E ratios in excess of 6:1.170
19-norandrostenedione
Biochemical/Physiological Effects.  19-
norandrostenedione is a substance that is
converted in the body to a steroid.  Ingesting it
leads to conversion in the liver to 19-
nortestosterone, also known as nandrolone.171
Very small amounts of nandrolone are normally
present in the body and detectable in the urine.
In 1999, 343 positive urine samples for
nandrolone were reported in international sports.
Nandrolone is the active ingredient in the
injectable anabolic steroid that was so widely
abused in the 1980s, Deca-Durabolin.
Therapeutic Uses.  There are no known
therapeutic uses of 19-norandrostenedione.
Effects on Athletic Performance.  Once
metabolized, it has effects on athletic
performance similar to androstenedione.172  19-
norandrostenedione is banned by the same sports
organizations banning androstenedione.
Potential Adverse Effects.  Side effects of 19-
norandrostenedione appear to be similar to
androstenedione and may include testicular
atrophy in males and masculinization in
women.173
Testing.  Urine testing is used to detect the use
of 19-norandrostenedione.  Recently, the
tolerance levels for the test were disputed by
Federation Internationale de Football
Association (FIFA) claiming that stress can
result in higher levels.  There have been many
high profile cases of positive nandrolone tests
recently; many of the athletes who tested
positive have claimed that it was due to the
unwitting ingestion of meat containing
nandrolone or of 19-norandrostenedione in
dietary supplements.174  A metabolite of 19-
norandrostenedione is found in the urine of
females using birth control medications
containing the steroid norethisterone.175
Use of the injectable oil-based nandrolone
(Deca-Durabolin) may be detected in the urine
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up to nine months following last use.
Nandrolone from contaminated meat or oral
dietary supplements are detected in the urine for
no longer than five days following ingestion.176
Current testing technology cannot differentiate
between natural, pharmaceutical, diet, or
supplement forms of nandrolone.
Beta-Hydroxy Beta-Methylbutyrate (HMB)
Biochemical/Physiological Effects.  Marketed
as a "Protein Breakdown Suppressor," HMB
(beta-hydroxy beta-methylbutyrate) purportedly
inhibits the breakdown of muscle proteins
during strenuous exercise and results in larger
gains in muscle function associated with
resistance training.177  However a more recent
study of experienced resistance-trained males
found that HMB supplementation during
resistance-training does not have any effect on
body composition or strength.178  Further
research needs to be done.
Therapeutic Uses.  There are no known
therapeutic uses of HMB.  However, a recent
study found that HMB supplementation appears
safe in humans at three grams per day, and that it
may decrease cardiovascular risk factors such as
total cholesterol, LDL cholesterol and systolic
blood pressure.179  Caution should be taken
when interpreting these results until further
studies replicate the findings.
Effects on Athletic Performance.  HMB is
attractive to athletes and body builders because
of manufacturers' claims that it increases lean
body mass and strength coincident with
strenuous exercise and is not banned by sports
organizations.  One study found that subjects
given HMB in addition to resistance training
increased the amount of weight they could lift
while a second group of subjects increased their
fat-free mass.180
Potential Adverse Effects.  Not much is known
about HMB's potential side effects.  Before any
study was ever published in any peer-reviewed
literature, it was brought to market based on an
abstract of a single study involving 28 human
test subjects receiving HMB over a three week
period encompassing two different dosages.181
At the time HMB came to market, the only
claims to product safety were animal studies and
the fact that no adverse effects were noted in the
28 human subjects.182
Testing.  Not tested for currently.
Masking Agents and Methods of
Beating Drug Testing
Athletes can employ a variety of methods to beat
tests.  In general, however, this type of in-
competition cheating, with observed collection,
is very difficult.
The most commonly used masking agents are
diuretics for their ability to dilute the presence of
other banned substances in urine, and
Probenecid because it blocks the excretion of
some steroids preventing detection in drug
tests.183  Other methods designed to beat testing
such as adding adulterants to the sample and
catheterization also are illegal.
Diuretics
Biochemical/Physiological Effects.  Diuretics
are drugs that increase the rate of urine
formation and accelerate water loss from the
body.  They dilute the urine in the body and thus
reduce the concentration of drugs present in the
urine sample so that they will be missed in the
drug test.
Therapeutic Uses.  Diuretic drugs often are
prescribed to treat congestive heart failure, high
blood pressure, and edema (an abnormal
accumulation of the fluid that fills the spaces
between the cells of body tissues).184
Effects on Athletic Performance.  In addition
to use to dilute and thus confound a drug test,
athletes use diuretics to achieve rapid weight
loss in sports where weight categories are
involved.  Although these are the primary uses
of diuretics, there is a study that documented
that athletes given diuretics significantly
improved their vertical jumping ability.185
Males who participate in weight-category sport
such as wrestling, boxing, martial arts, and
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horse-racing may use diuretics to deliberately
drop up to three to six percent186 of body weight
prior to competition in order to qualify in the
lowest weight category possible.  This result is
often achieved by combining diuretics with
some combination of exercise, food and water
restriction, heat exposure (e.g., sauna), self-
induced vomiting and laxatives.  Body builders
use diuretics to obtain a "cut" or fit appearance.
Similar methods are used by female athletes in
sports such as gymnastics, figure skating and
dancing.  Females also may use diuretics to
manage premenstrual fluid retention.  For female
athletes, diuretics may be used in conjunction
with excessively strict dieting for weight loss, a
practice common among those suffering from
anorexia nervosa (the obsessive need to become
thinner).
Potential Adverse Effects.  Most diuretics have
the effect of causing excessive and potentially
life threatening changes in potassium levels in
the body.  Additional adverse effects include
dehydration, muscle cramps and decreased
blood volume frequently associated with a drop
in standing blood pressure.187
Testing.  Urine testing is typically used to detect
diuretics both in-competition and out-of-
competition no-notice, testing.  Diuretics are
tested for in weight specific sports events or if a
very dilute urine sample is produced  The period
of detection of diuretics in urine by is up to five
days after last use.188
Adulterants
Commercially available agents can be added to a
urine sample to interfere with testing of drugs of
abuse.  Adulteration is possible when there isn't
a supervised collection process that can
guarantee the purity of the sample.  There are
reports that the ingestion of particular
compounds may cause false-negative results for
drug screens in urine; however, most ingested
products are generally not effective in beating
drug tests.  The use of adulterants underscores
the need for guarantees of the integrity of the
sample.
Catheterization
Catheterization is used to empty the bladder so
that it can be refilled with a clean urine sample.
This is a drastic measure that is both painful and
requires advance notice of a drug test.
Catheterization must be done very close to the
time the sample is taken since the athlete's own
urine will be produced and the clean urine will
become contaminated.
Another way urine is substituted is by inserting a
bulb filled with clean urine into the vagina
which would burst when muscles are contracted.
This method of beating the tests would not be
very likely during a competition because the
bulb would probably not be able to withstand
strenuous activity.189
The Future for Drug Testing
New drugs are constantly being developed to
give the user a competitive edge yet still elude
detection or avoid sanction.  Sports governing
bodies have been two steps behind, scrambling
to develop tests once widespread use has already
been noted.
A more potent deterrent than current testing
practices would be to use drug testing methods
that have longer detection windows or media
that contain a higher concentration of drugs.  For
example, blood tests, although more invasive,
have higher concentrations of drugs compared to
urine making it harder to mask drug use.190
Another option, supported by former gold
medalist and current Chief of the US Anti-
doping agency, Frank Shorter, is to freeze urine
samples and subject them to each new detection
test that is developed.191  The threat of having a
medal stripped away at some future date and
one's reputation tarnished may provide a
deterrent to doping.  Whether this is feasible,
due to chain of custody concerns and
degradation of samples over time, is unknown.
Other forms of testing require more research.
Hair testing still remains controversial.  Some
studies have documented that hair testing
provides a much larger window of detection than
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urine, blood or saliva testing192 and is especially
powerful for detecting amphetamines.193
However, other research shows that different
hair pigmentation produces different results:
darker, coarser hair tends to show drug use for
longer and at lower concentrations.194
Another area of research underway is a test to
identify performance-enhancing properties of a
substance rather than to simply test for the
presence of a substance.195  Such a test would
eliminate the problem of chemists minutely
changing the structure of a drug (i.e.,
androstenedione, 19-norandrostenedione, 19-nor
androstenediol, etc.) to retain the same effect but
avoid sanction.
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Chapter IV
How Big is the Doping Problem in Olympic Sports?
Estimates of prevalence of doping among
Olympic athletes vary widely.  The International
Olympic Committee (IOC) and several National
Federations administering drug testing programs
indicate that less than three percent of athletes
test positive for any banned substances.1  Other
credible sources indicate use to be very much
higher, including one report where Olympic
officials estimate the actual number at 10
percent.2  Some veteran athletes put the figure at
closer to 30 percent.3  At this rate, over 3,000
athletes would engage in doping for the 2000
Sydney Games.  In cycling, prevalence estimates
have been documented to reach as high as 45
percent.* 4  Some athletes, coaches and trainers
believe that drug use in sports is much higher
than any of these statistics suggest - up to 80 or
90 percent in some sports.5  While each of these
data sources has particular strengths and
limitations, together they present a disturbing
picture of doping in Olympic level competition.
Moreover, some experts believe doping among
elite athletes will only get worse as
technological advances continue to be made at
breakneck pace.
* The International Federation for cycling, Union
Cycliste Internationale (UCI), has stated that all
riders who tested positive for a banned substance
during the cited competition proved the drugs were
being taken under medical supervision and within
UCI rules.
You can produce statistics showing that we have
tested 35,000 persons in one year, as the IOC
did in 1987, and only some eight or ten were
caught.  But that is, of course, because
everybody knows the game.6
--Hans Skaset, President
Norwegian Confederacy of Sport
®
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Drug Testing Results Under-Report
Use
Drug-testing statistics present a relatively benign
picture of the size and magnitude of the doping
problems in sport.  Experts examining the use of
prohibited substances by Olympic level athletes
believe that most prevalence estimates under-
report actual use.  While documented and
reported positive test results are an obvious and
readily accessible means for making prevalence
estimates of substance use among Olympic
athletes, these data are limited in three very
important ways.
First, drug-using athletes are often very
knowledgeable about how to circumvent the
tests.  In the case of in-competition testing,
athletes can determine when to discontinue use
of a drug prior to testing so as to allow the
metabolites of the drug to clear the body and
avoid a positive test result.7  In out-of-
competition testing, for example, an athlete can
self-monitor his or her testosterone/
epitestosterone ratio and manipulate drug intake
to ensure a test result below the maximum
allowable ratio of 6:1.  In such cases, the
maximum allowable threshold transforms from
an absolute limit intended to allow for normal
variation between individuals into a target to be
approached as closely as possible.
Second, testing technologies are not yet capable
of positively identifying all forms of substance
use.  For example, despite their purported high
level of use, there is currently no accepted,
reliable and valid urine test for detecting doping
with human growth hormone (hGH) or insulin-
like growth factor (IGF-1).  The ability of
athletes to circumvent tests and the lack of
reliable and valid testing methods for several
substances lead most experts to conclude that
only the stupid actually get caught and that drug-
testing statistics yield a large number of false-
negative results.
Third, the bodies conducting athlete drug testing
must be unequivocally motivated to detect and
report performance-enhancing drug users.  One
of the primary objectives of the IOC,
international sports federations and National
Governing Bodies is the promotion of sport.
This goal is not always compatible with the goal
of detecting and disclosing performance-
enhancing drug use in star athletes.  To the
degree that sports governing bodies are limited
in their ability to separate their dual functions as
the primary promoters of sport and police of
drug use among their athletes, testing statistics
may under-report actual use.  Drug-testing
statistics probably should best be viewed as an
absolute minimum estimate of the problem of
doping in sports.
International Olympic Committee
(IOC) Drug Testing Results
The IOC conducts drug tests both in- and out-of-
competition.  Out-of-competition, short or no-
notice testing is considered absolutely essential
in order to detect the use of banned training
drugs and/or prevent athletes from ceasing drug
use in sufficient time to clear drug metabolites
from their systems before an in-competition
drug test.
Table 4.1
Positive Test Results at the Olympic
Games by Sport (1968-1996)
Sport
Number of
Positive Results
Winter Games
Hockey 3
Nordic Skiing 2
Summer Games
Weightlifting 20
Track and Field 11
Volleyball 4
Modern Pentathalon 3
Cycling 2
Judo 2
Wrestling 2
Basketball 1
Shooting 1
Swimming 1
Yachting 1
Source:  International Olympic Committee (as cited in
Shipley, A. 1999, p. D11).
Random testing is a joke.
--Head Coach of elite level competitors
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International Olympic Committee (IOC) reports
indicate that very few athletes fail drug tests in
Olympic competition.  Since drug controls were
instituted at the Mexico City Summer Olympic
Games in 1968, out of 14,678 tests performed,
only 53 doping cases (0.0359 percent) have ever
been detected and reported.  Of these 53 cases,
48 (90.6 percent) occurred during the Summer
Olympic Games while only five such incidents
(9.4 percent) were recorded during Winter
Games.  Athletes competing in weightlifting and
track and field comprised significantly higher
proportions of positive doping cases than
athletes in other sports (Table 4.1).
No doubt due in part to their noted performance-
enhancing qualities, anabolic-androgenic
steroids (AASs) and stimulants accounted for
the overwhelming majority of positive doping
cases.  In total, AAS cases comprised 49.1
percent of the positive doping cases with
stimulants following at 34.0 percent.  Diuretics,
which can be used to mask the use of other
substances, accounted for the next largest group
of positive doping cases at 7.5 percent  (Table
4.2).
The IOC-accredited laboratories annually report
the number of samples tested and the number of
positive tests for both in- and out-of-competition
(OOC) testing.  The number of samples tested
increased by more than 36 percent between 1989
and 1990.  Since then, the total number of
samples increased annually through 1994.8  The
percentage of samples collected using short and
no-notice testing also increased from 1986 to
1994, reaching 43 percent in 1994 at a slower
rate.9
The percentage of samples that tested positive
for stimulants and anabolic androgenic steroids
(AASs) stabilized at approximately 0.4 percent
and one percent, respectively.10  In 1994,
diuretics, beta-blockers, and narcotics together
accounted for 0.17 percent of the positive tests,
and nandralone plus testosterone-to-
epitestosterone ratios (T/E) greater than 6:1
accounted for approximately 52 percent of the
positive test results related to AASs.11  At the
time, detection of nandralone was decreasing
while detection of T/E ratios greater than six
was increasing.12  Over-the-counter (OTC) drugs
accounted for 50 to 60 percent of the stimulants
detected.13
Table 4.3 reflects all sports and all levels of
competition and in some countries the data
include body-building and other non-Olympic
sports with high risk for drug use.
Consequently, these data cannot be used to draw
conclusions about any particular sport.  Informal
reports from sports federations that conduct
rigorous, year-round, short-notice testing detect
few positive cases.14
Table 4.2
Positive Test Results at the Olympic
Games by Substance
(1968-1996)
Substance
Number of Positive
Test Results
Alcohol 1
Anabolic Agents
Anabolic Steroids 8
Nandralone 7
Stanozolol 4
Testosterone 3
Methandienone 2
Metenolone 2
Beta-2 Agonists
Clenbuterol 2
Beta Blockers
Propanolol 1
Diuretics
Furosemide 4
Narcotics
Codeine 1
Stimulants
Ephedrine 6
Amphetamine 3
Coramine 2
Femcamfamine 1
Phenylpropanolamine 1
Pemoline 1
Caffeine 1
Norephedrine 1
Mesocarb 1
Strychnine 1
Source:  International Olympic Committee (as cited in
Shipley, A. 1999, p. D11).
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Table 4.4 presents the absolute
number of positive test results
reported by IOC-accredited
laboratories between 1986 and 1996,
broken down by detectable
substance.
Consistent with previous findings,
these data indicate that for the most
recent year available anabolic
steroids have had the highest
incidence of identified use, followed
by stimulants and diuretics.
United States Olympic
Committee (USOC) Drug
Testing Results
In 1984, the USOC was the first sports
organization to begin conducting athlete drug
testing in the United States.  Between 1984 and
1995, the USOC conducted announced testing
for all major events at a rate of 3,500 samples
per year, with men accounting for about 70
percent of those tested.15  During those 11 years
there were 128 positive test results for steroids
and steroid-blocking agents (including 10
women), 12 positive test results for diuretics,
seven for beta-blockers, 15 for narcotics (mostly
codeine and propoxyphene) and 365 for
stimulants (0.89 percent of all tests).16  The
breakdown of the positive test results for
stimulants was:  over-the-counter drugs, 81
percent; cocaine, 6.6 percent; caffeine (greater
than 12 micrograms per milliliter), 1.6 percent;
amphetamines, methamphetamine,
isometheptene and nikethamide, 10 percent.17
Because the USOC conducts testing for both
national and international events held in the
United States, some of these positive results
were not among U.S. athletes.  Conversely,
USOC athletes were tested in other countries
and these results were not included.
To obtain more current information (i.e., post-
1995), The CASA National Commission on
Sports and Substance Abuse approached the
USOC with a request for updated statistics on
the number of tests performed and the number of
positive test results broken down by sport and by
drug.  The CASA Commission was not able to
obtain this information from the USOC.
Table 4.3
Annual Total and Out-of-Competition Drug Tests
Performed by the IOC
(1986-1994)
Tests % Positive
Year Total Number
of Tests
% Short or
No Notice Total Stimulants AASs
1986 32,982 NA 2.1 0.54 1.33
1987 37,882 17.4 2.3 0.79 1.38
1988 47,098 24.4 2.7 0.89 1.68
1989 52,379 28.0 2.2 0.97 1.17
1990 71,341 39.6 1.4 0.48 0.81
1991 84,088 40.5 1.1 0.26 0.66
1992 87,808 41.5 1.4 0.32 0.82
1993 89,166 39.3 1.7 0.38 1.06
1994 93,680 43.2 1.5 0.37 0.95
Source:  Catlin, D. H., & Murray, T. H. (1996).
Table 4.4
Annual Positive Test Results Reported by the IOC by Substance
(1986-1996)
Substance 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996
Anabolic steroids 439 521 791 611 579 652 717 995 891 986 1,131
Stimulants 177 301 420 508 340 221 277 339 347 310 281
Narcotics 23 55 58 76 62 72 102 48 42 34 37
Beta-blockers 31 33 8 6 8 10 12 13 15 14 6
Diuretics 2 9 57 45 37 47 70 66 63 59 54
Masking agents * 24 19 10 6 1 22 23 8 3 0
Peptide hormones * * * * 1 1 4 4 3 9 4
Total 672 943 1,353 1,256 1,033 1,004 1,204 1,488 1,369 1,415 1,513
* Not tested.
Source:  International Olympic Committee (as cited in Houlihan, B. 1999, p. 133).
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Comparative Drug Testing Results
from Australia and Canada
The Australian Sports Drug Agency (ASDA)
and the Canadian Centre for Ethics in Sport
(CCES) are national organizations with charters
to fight doping in sports.  As the administrative
bodies for doping control on the Australian and
Canadian Olympic Committees, the ASDA and
CCES are the Australian and Canadian
counterparts to the soon-to-be replaced Doping
Control Administration at the USOC.  For
comparative purposes, their drug testing
statistics are included here.
Published statistics from the ASDA indicate that
a total of 4,801 drug tests were conducted on
athletes between July 1, 1998 and June 30, 1999.
Of that total, 1,705 tests (35.6 percent) were
performed in-competition, and 3,096 (64.5
percent) were conducted as out-of-competition
tests.  Athletes tested positive in less than one
percent of the tests.  Anabolic agents, beta-2
agonists and stimulants comprised the largest
number of positive test results (Table 4.5).
The CCES conducted approximately 1,800
drug tests on athletes through its domestic
program in 1997 (the latest year available) of
which close to 80 percent were
unannounced.18  According to their published
testing results for that year:  anabolic agents
comprised 66 percent of the doping
infractions, stimulants accounted for 17
percent, refusals to submit to testing made up
13 percent of the "positive" test results and
diuretics comprised four percent.19  During the
entire period from 1987 to 1997:  anabolic
agents comprised 74 percent of all doping
infractions, refusals to submit to testing
accounted for 13 percent overall, stimulants
made up nine percent of the positive test
results and diuretics comprised four percent.20
These drug-testing results differ slightly from
those found by the USOC.  More specifically,
drug-testing results from the USOC indicated
stimulants to have the highest levels of athlete
use (roughly twice that of the next class of
substances), followed by anabolic steroids,
narcotics, diuretics and beta-blockers.  Findings
from the drug-testing results from Australia and
Canada indicate use of anabolic steroids to be
the most prevalent, followed by stimulants and
diuretics.
USA Track and Field Drug Testing
Results
USA Track and Field (USATF) is the national
governing body for track and field, long distance
running and race walking in the United States.
According to testimony before The CASA
National Commission on Sports and Substance
Abuse from an official at USATF, in 1998, the
USATF's anti-doping program administered 737
tests with seven positive results (0.949
percent).21  Testing is conducted by the USOC
and the International Amateur Athletic
Federation for the USATF.  In 1999, through
December 15th, they administered 876 tests with
11 positive results (1.26 percent) that have made
it through the adjudication process.22
The percent of positive test results for men was
roughly twice that of women.  However, the
percent of positive results in women increased
significantly (over 20 percent) between the two
years while it decreased in men over the same
time period (Figure 4.A).23
Table 4.5
Positive Results Reported by
Austrialian Sports Drug Agency
(July 1998-June 1999)
Substance Total
Number
% of Positive
Results
(N=43)
% of Total
Tests
(N=4,801)
Anabolic agents 12 27.9 0.25
Beta-2 agonists 12 27.9 0.25
Diuretics 2 4.7 0.04
Narcotic Analgesics 1 2.3 0.02
Stimulants 11 25.6 0.23
Cannabinoids 2 4.7 0.04
Failure to comply 3 7.0 0.06
Source:  Australian Sports Drug Agency. (2000b).
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According to statistics provided by USATF
officials, stimulants are the most significant
problem facing USA Track and Field (Figure
4.B).24  While substances detected include
steroids, stimulants and diuretics, most of the
athletes tested positive for the sympathomimetic
amines (particularly pseudoephedrine) found in
over-the-counter cold medications.  Many of
these positive test results were said to be found
in younger, high school age athletes who may
not have been fully aware of the rules regarding
these substances.  Use of a masking agent and
failure to provide a urine sample are considered
to be equivalent to a positive test result.
Government Reports of Doping
Recent findings from government
investigations depict doping as a problem of
greater magnitude than that suggested by
drug-testing statistics.  During governmental
hearings, current and former athletes,
coaches and sport federation officials, with
few exceptions, have supported the notion
that there is a significant doping problem.25
In the worst possible scenario, reports
indicate that governments, in obvious
violation of their public trust, have even
sponsored doping activities in their
athletes.26
As with other data sources regarding doping in
sport, government investigations are not without
limitations.  From a methodological perspective,
using the volunteered opinions and observations
of a relatively small sample of individuals,
selected in a nonrandom manner, to estimate the
extent of doping is less than ideal.28  Individuals
who use or have used drugs and who serve as
informants may project their behavior onto
others in an attempt to rationalize their drug use,
resulting in an overestimate of drug use.29
Conversely, athletes and others may refuse
to cooperate with government inquiries to
shield themselves or to protect their
teammates, coaches, federations, and/or their
individual and collective reputations,30
resulting in an underestimation of use.
Government reports on athlete drug use have
originated from around the world.
Prevalence estimates from this data source
range from findings similar to drug testing
statistics from the National Governing
Bodies of sport on the low side to 90 percent
for some government-instituted doping
programs.31  In Germany, the former sports
I feel sorry for Ben Johnson.  All
sportsmen--not all, but maybe 90%,
including our own--use drugs.27
--Anonymous Soviet Coach
October 1988
Figure 4.B
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Source:  Jill Pilgrim, General Counsel and Director of Business Affairs, USA Track and Field
(personal communication,December 22, 1999).
Figure 4.A
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chief of the German Democratic Republic (the
"Sportfuhrer") was recently convicted for
employing a systematic doping policy and
administering anabolic steroids to thousands of
athletes, many of whom were not even aware of
what they were taking.32  During U.S.
Congressional hearings on performance-
enhancing drugs, current and former athletes as
well as coaches and sports federation officials
testified that significant doping problems exist at
all levels.33
After 91 days of testimony initiated as a result of
the Ben Johnson doping incident in the 1988
Seoul Olympic Games, Canada's Dubin
Commission concluded that "the noble
sentiments and lofty ideals proclaimed in the
Olympic Charter are a far cry from the reality of
international competition."35  They also referred
to a "conspiracy of silence" and a "pact of
ignorance" among those in sport when it comes
to discussing drug use as a result of their
investigations.36  During the 1998 Tour de
France, cycling's premier race, a team masseur
for the French-based Festina team submitted
documentation and testified to authorities about
how he assisted hundreds of elite cyclists take
performance-enhancing substances over the
course of 20 years.37
Journalistic Accounts and Expert
Testimony About Doping
The writings and testimonials of athletes and
others involved with sport also confirm that
doping is a serious problem throughout
international sport.38  Presenting the same
potential problems as findings from
governmental reports, journalistic reports must
be viewed judiciously.  However, given the
sheer number and scope of credible reports that
have been written over the past four decades
regarding athlete substance use, many people no
longer view significant achievements in sport to
be achievable without the help of some
substance.  Such reports have become
ubiquitous.  Journalists, using primarily the
personal observations, accounts, or opinions of
self-selected informants, both anonymous and
attributed, have detailed a sustained epidemic of
drug use in sport at all levels.39  According to the
Assistant Managing Editor for Sports at The
Washington Post, "A week rarely goes by where
we don't have a front page story on drugs--and a
day doesn't go by where we don't have an item
on drugs."40  Prevalence estimates from
journalistic reports reach up to 90 percent.41  To
illustrate, consider the following recent
headlines:
• "Positive on testing: But will the Olympic
Games get clean this year - or ever?" from
U.S. News and World Report, August 14,
2000
• "IOC Approves EPO Tests for Sydney"
from The Associated Press, August 1, 2000
• "Chinese world-record holder loses Olympic
spot after drug test" from The Associated
Press, July 6, 2000
• "New Olympic Doping Accusations Cast
Shadow" from The New York Times, June
22, 2000
As doping practices have grown and become
more public, particularly in the Olympics, public
perception of athletes is changing.  Outstanding
performances are viewed with skepticism and
the question of drug use always emerges.
According to Don Talbot, coach of the
Australian swim team, "It's an unfortunate fact
of life now that anybody that swims fast or
makes big improvements, immediately comes
under suspicion.  It's really sad because good
athletes should be able to glory in their wins and
not be criticized for them."42
China Cuts 40 From Games Team Amid
Drug Concerns
China has informed Australian Olympic
authorities it has cut 40 athletes and officials--10
percent of the total--from its national team for the
Sydney Games starting next week....34
--Reuters
September 5, 2000
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Chapter V
The Rules:  Standards and Enforcement
Over the past three decades, the public has heard
representatives of the governing bodies of
Olympic and international sport* state on
numerous occasions their commitment to drug-
free competition.  These regulatory bodies have
developed extensive rules, monitoring processes
and sanctioning systems.1  Since 1968, Olympic
governing bodies have banned hundreds of
substances.  Yet, doubts about the effectiveness
of these efforts plague Olympic sports.
Governing Bodies
Governing bodies in sport deem the use of
performance-enhancing drugs incompatible with
the basic principles of athletic competition.
They ban these substances because they threaten
the health of athletes and provide an unfair
advantage--allowing the drug user to cheat by
surpassing "natural" performance levels.
Governing bodies of international sports face,
however, complex problems in developing,
implementing and enforcing an effective anti-
doping program.  From a legal and regulatory
perspective, some of the problems which must
be solved to make a fair and effective drug-
testing program a reality include:3
• Keeping pace with fast-breaking
developments in the pharmacology of
performance enhancement and deciding
which substances to ban,
* The International Olympic Committee (IOC),
International Sports Federations, National Olympic
Committees and National Governing Bodies.
The fear is that athletic competition will become
a competition between pills, not skills, and that
the sports champions of the future will be
chemically created.2
--James B. Jacobs and Bruce Samuels
Center for Research in Crime and Justice
New York University School of Law
®
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• Assuring timely and effective notice to
athletes as to which substances are banned,
• Developing highly accurate tests for the
performance-enhancing substances in the
body,
• Overcoming the logistical problems of
obtaining and transporting athletes' testing
samples,
• Establishing and accrediting testing
laboratories around the world, and
• Developing a system of enforceable
sanctions.
The sports governing bodies are not experts in
the field of drug testing.  Addressing these issues
is further complicated by the conflict of interest
inherent in having the governing bodies
responsible for promoting their sport be the
primary monitors and adjudicators of athlete
drug use.
The International Olympic Committee
(IOC)*
The IOC, headquartered in Lausanne,
Switzerland, is the central governing body and
"supreme authority" in Olympic sport.4  It
creates rules and procedural guidelines for
Olympic decision-making, selects host cities for
the Olympic Games, determines qualifications
for athletic participation and establishes
procedures for electing its own officers and
representatives.5  The IOC consists of 113
members selected from countries that have a
formally recognized National Olympic
Committee.6  IOC members are representatives
of the IOC in their home countries, not national
delegates to the IOC.
The IOC's powerful Executive Board, composed
of a President, four Vice Presidents and ten at-
large members, decides "all matters of doubt or
* See Appendix A for international sports
organization chart.
dispute that are of a nontechnical nature
concerning the Olympic Games and the Olympic
Movement."7  The Board "may take action on its
own initiative or upon request of a member of
the IOC, a National Olympic Committee, an
International Federation, or an Organizing
Committee for an Olympic Games."8  In
addition to this broad jurisdictional power, IOC
decisions are not reviewable because it has
"final authority on all questions concerning the
Olympic Games and the Olympic Movement,"
and that includes all questions related to
doping.9
History.  A central issue faced by the IOC is
determining what substances to ban.  This
process appears to date to have been more
reactive and anecdotal than consistent and
planned.  Even prior to the advent of the Modern
Olympiad in 1896, the use of substances by
athletes to enhance personal performance
appeared to be generally common practice
within the international sporting community.11
Extensive and frequently unregulated
experimentation with drugs during World War II
(particularly amphetamines and steroids) greatly
increased scientific knowledge about the
properties of these drugs and demonstrated the
opportunities for their use outside a therapeutic
context.  Throughout the 1950s, cyclists were
the main group of athletes thought to be heavily
involved in drug abuse, though drug taking was
also considered to be rife in professional boxing
and several speed-skaters became ill through the
over-use of amphetamines during the 1952
Helsinki Olympics.12
Until the mid-1960s, however, concerns about
"doping" were confined to a few physicians and
medical researchers within sport.  Their private
If there's bribery in [selecting] Olympic cities,
there's bribery in drug testing.10
--Mark Tewksbury, three-time Olympic
medalist, member of the Canadian Olympic
Association and of international swimming's
athlete commission, during his resignation from
his Olympic posts in protest over "the inability
of the IOC to seriously clean its own house"
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concern had yet to reach the public forum.13
Although some countries began expressing
concern that drugs were harming both the
integrity of sports and the health of athletes, it
was not until a Danish cyclist died during the
1960 Games in Rome, reportedly from ingesting
amphetamines mixed with a nicotine acid
derivative administered by his coach, that
international sports federations perceived a
serious threat.14
Early Response to Doping.  In 1961, the IOC
established a Medical Commission to examine
the problem of doping and, in 1962, passed a
resolution condemning the practice of doping in
sports.15  At a meeting of a convention of the
Council of Europe sports governing bodies in
1963, the IOC adopted a definition of doping:
"the administration to, or the use by, a
competing athlete of any substance foreign to
the body or any physiological substance taken in
abnormal quantity or by an abnormal route of
entry into the body, with the sole intention of
increasing in an artificial and unfair manner his
performance in competition."16  There were
serious difficulties with elements of this
definition.  What is the practical meaning of
"any substance foreign to the body?" How does
one scientifically determine what are abnormal
quantities or routes of administration?
Ambiguity within this definition, especially in
the absence of sophisticated screening
methodologies, complicated the work of the
Medical Commission.
First Doping Control Policies.  The 1964
Olympics in Tokyo marked the first IOC attempt
to initiate some form of doping control.17  The
International Olympic Committee, however, did
not become a committed and active participant
in the anti-doping movement until after the
televised death of British cyclist Tommy
Simpson, caused by the illegal use of
amphetamines during the 1967 Tour de France.18
The Medical Commission of the IOC was
reorganized in 1967 with a mandate to establish
a medical control service for the 1968 Winter
and Summer Olympics to study the issue of
doping controls and identify the assistance that
could be provided to athletes in developing
countries.19  Three basic principles governed the
work of the IOC Medical Commission:
(1) protection of athlete's health; (2) defense of
sports ethics; and, (3) equality for all
participants at the moment of competition.20
In the 1960s, early drug testing efforts
concentrated primarily on the sport of cycling
and the detection of amphetamines--the most
widely used drug at that time.  Testing methods
were relatively unsophisticated and often
produced inaccurate results having, therefore,
little deterrent effect.  During this time,
awareness of the use of anabolic steroids was
growing.  There was, however, no reliable test
for this class of drugs.21
Expansion of Doping Control.  The first
Olympic Games with relatively comprehensive
testing across all sports were the 1972 Munich
Games.  Tests were conducted for stimulants
(e.g., amphetamine, ephedrine) and narcotics
(e.g., heroin, morphine).  Even though it was
common knowledge that the major drugs abused
by athletes had shifted from stimulants to
anabolic steroids, the continued lack of a reliable
test to detect steroid use precluded both
screening for these drugs and including them on
the IOC's list of banned substances.23
During the 1970s, a reliable test for many drugs
in the steroid class was developed.  As a result,
they were added to the IOC's list of banned
substances in 1975 and first officially screened
for during the 1976 Montreal Games.24
In 1981, the Medical Commission created the
Doping and Biochemistry of Sport Sub-
commission to prepare the list of banned
substances and establish testing procedures.
Outside sources from all parts of the sports
world were asked to propose substances for the
banned list.25
...in the last decade 27 Chinese swimmers
have tested positive, at world meets, for
banned substances.  The world swimming
federation, regarded as tough on drugs,
caught them.  The IOC didn't.22
-46-
As testing technologies improved, the IOC
gradually expanded its prohibited substances
list.  Testosterone and caffeine were added in the
early 1980s, beta-blockers (e.g., propranolol,
acebutolol) and blood-doping (i.e.,
administration of blood, red blood cells or
related blood products to an athlete) in 1985,
diuretics (e.g., acetazolomide, bumetanide) in
1987 and peptide hormones (e.g., human growth
hormone) in 1990.26
Current Doping Control Policies.  Effective
January 1, 2000, the IOC's Anti-Doping Code
prohibits the following classes of drugs:
(1) stimulants, (2) narcotics, (3) anabolic agents
(including anabolic androgenic steroids and
beta-2 agonists), (4) diuretics, and (5) peptide
hormones, mimetics and analogues.  Under
certain circumstances, specified in the Code, the
following are also prohibited:  cannabinoids,
local anaesthetics, corticosteroids and beta-
blockers.27  (These classes of drugs and their
pharmacology are described in Chapter 3, The
Pharmacology of Competition.).  In addition to
these substances, the practices of blood doping
and pharmacological, chemical and physical
manipulation to mask or otherwise influence
drug test results are also prohibited by the anti-
doping policy currently in effect.  (See
Appendix B for a sample summary of drug
regulations.)*
International Federations (IF)
The IOC delegates all technical matters of a
particular sport to the International Federation
(IF)--the International Governing Body--of that
sport.  An IFs' responsibilities include: selecting
Olympic officials, determining athlete
eligibility, defining the technical rules for
international competition, imposing sanctions
* Appendix B contains summaries of the current drug
regulations for the IOC, International Amateur
Athletic Federation (IAAF), Union Cycliste
Internationale (UCI), and Federation Internationale
de Football (FIFA), including criteria for the
selection of athletes for testing and sanctions.  Where
appropriate, specific substances and procedures that
are prohibited, including cut-off levels for the
applicable substances, are included.
for rule violations, drug testing athletes and
resolving disputes.  The International Amateur
Athletic Federation (IAAF) is the IF for Track
and Field, the Union Cycliste Internationale
(UCI) is the IF for cycling, the Federation
Internationale de Football (FIFA) is the IF for
soccer, etc.  To be recognized by the IOC, an
International Federation must agree to comply
with the Olympic Charter, show compliance
with IOC criteria and receive approval by the
IOC Executive Board.  The IOC has the
authority to revoke recognition if the
International Federation fails to comply with any
of the requirements.28
The National Governing Bodies (NGBs) from
each country for a particular sport comprise an
International Federation's membership.29
National Olympic Committees (NOC) and
National Governing Bodies (NGB)
A National Olympic Committee is responsible
for its country's representation at the Olympic
Games.  To be recognized by the IOC, a
National Olympic Committee must agree to
abide by IOC rules.  Established by Congress in
1896, the United States Olympic Committee
(USOC) is the National Olympic Committee for
the United States.30
The U.S. Congress greatly expanded the USOC's
authority to develop and govern amateur sports
in the United States by passage of the Amateur
Sports Act of 1978.  The Act allows the USOC
to delegate much of its sport development and
governance responsibilities to the National
Governing Bodies (NGBs) of each sport.  An
NGB is the sports governing body for a
particular sport within a single country.  For
example, USA Track and Field is the NGB for
track and field within the United States.  To gain
recognition as an NGB in the United States, an
organization must receive USOC approval;31
however, the NGBs operate independently of the
USOC.32  If approved, the USOC recommends
the NGB to its respective International
Federation as the U.S. representative for that
sport.33
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Overlapping Doping Regulations and
Sanctions
Depending on the country and sport, each
governance level (i.e., the IF, NOC and NGB)
has its own set of doping regulations, testing
practices, and sanctioning systems.  However, in
addition to complying with the rules of its
National Olympic Committee, an NGB also
must conform to the rules and regulations of its
International Federation.34  Similarly, in doping
matters, athletes must comply with the
regulations, testing practices and sanctioning
systems of all governing bodies relevant to both
their country and sport.
Critics argue that these differences in doping
policies are a major part of the problem with the
anti-doping system currently in place in
international sports.  For example, depending on
the specific event, sport, and country in
question, an athlete may be subject to either:  in-
competition or out-of-competition testing with
or without advanced notice, or some
combination of these different testing programs.
The selection criteria for athletes to be tested can
range from being totally random to involving
solely the top finishers in a competition or those
considered to be "reasonably suspicious" of
having used drugs.
All International Federations ban all the major
classes of performance-enhancing substances
and masking procedures, but there can be subtle
differences in how certain substances may be
treated in terms of cut-off levels (e.g.,
testosterone to epitestosterone ratios are
allowable up to a level of 6:1 under IOC
regulations, but can reach as high as 10:1 before
being considered a doping infraction under
International Tennis Federation rules35) and/or
other restrictions (e.g., alcohol being banned in
the Olympics only for shooting and archery
events).  These differences can cause several
problems as athletes must be informed
continuously of additions and changes to the
banned substances lists.
Sanctioning systems vary greatly as well, and
may or may not depend on the substance abused.
For example, the regulations of the international
federation for cycling (i.e., Union Cycliste
Internationale) impose differential sanctions
depending on gender and the level of
competition during which a doping infraction
occurred.  Such discrepancies cause a great deal
of confusion for everyone involved with
preventing the use of banned substances.  From
the Governing Bodies' perspectives, an
international arena coupled with a multitude of
different governance levels makes the uniform
application and enforcement of sanctions
difficult to implement.  From the athletes'
perspectives, however, failure to do so creates a
lack of faith in the fairness of the anti-doping
system.
The World Anti-Doping Agency (WADA)
In recognition of the fact that the Olympic
governing bodies cannot regulate all aspects of
the fight against doping in sport, the World Anti-
Doping Agency (WADA) was established on
November 10, 1999 in Lausanne, Switzerland.36
The Agency's principal task is "to coordinate a
comprehensive anti-doping program at the
international level, laying down common,
effective, minimum standards, compatible with
those in internationally recognized quality
standards for doping controls, particularly with
regard to out-of-competition controls, and
seeking equity for all athletes in all sports and in
all countries."37  For these purposes, the
International Sports Federations "while
preserving their autonomy and their own
authority, agree to cooperate with the Agency
and coordinate their respective anti-doping
programs with it in order to ensure that
duplication is avoided and that the same
application is achieved worldwide."38  Thus,
working primarily with and through the IOC, the
International Sports Federations, the National
Olympic Committees, governments and the
athletes, WADA's goal is to seek and obtain
from all of the above the moral and political
commitment to follow its recommendations.
When fully appointed, WADA's Board will
consist of equal representatives from the
Olympic Movement and public authorities (i.e.,
governments, intergovernmental organizations
and other public and private bodies fighting
against doping in sport).39
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The WADA Board of Directors is comprised of
32 members, 16 from the Olympic Movement
and 16 from public authorities; there are
provisions for adding three additional members.
To help launch WADA, IOC Vice President
(and Chairman of the IOC Marketing
Commission) Richard W. Pound (Canada) was
appointed WADA's first Chairman and the IOC
provided US $25 million for the initial two years
of WADA operations.  At the end of these two
years, Mr. Pound is expected to step down and
the public authorities are expected to contribute
some share of WADA's funding.  The exact
division of responsibility for WADA's funding
after the initial two years has yet to be
determined.40
Despite its laudable goal of coordinating a
comprehensive, international doping program,
WADA's role is ultimately limited to making
recommendations to the IOC.41
The United States Anti-Doping Agency
(USADA)
On December 3, 1999, the USOC Select Task
Force on Drug Externalization called for the
creation of a new independent organization, the
United States Anti-Doping Agency (USADA) to
enhance the credibility and effectiveness of U.S.
efforts to deal with the issue of doping in elite
sports.  The Task Force concluded that a new
organization could "expand and improve upon
the programs for anti-doping that currently
exist" and alleviate the "inherent conflict of
interest between the NGBs and their athletes"
that results from the NGBs prosecuting doping-
related infractions.42  The creation of the
USADA presents the opportunity to "support
athletes and to seek harmonization of the
procedures and practices of the NGBs and their
International Federations and the IOC."43
As of October 1, 2000, the USADA will replace
the USOC's current Anti-Doping Administration
and assume the task of developing a national
anti-doping program in the United States
relating to U.S. participation in the Olympic,
Pan American and Paralympic Games.  The
USADA also will be responsible for sample
collection, testing, adjudication, sanctions and
research for elite level sports in the U.S.  The
USADA will be incorporated as a nonprofit,
nonmember corporation.  The Board of
Directors will be comprised of nine individuals--
two members elected by the USOC Athletes
Advisory Council, two members elected by the
USOC NGB Council, and five public sector
members.44
The new proposed adjudication procedures
differ from current processes in three important
ways:  (1) prosecution will be the responsibility
of an independent organization with no
conflicting interest in the outcome; (2) all
findings will be made public upon completion of
the hearing process; and, (3) public reports
indicating the number of positive tests and
adverse findings will be issued periodically by
USADA.  Appendix C presents the adjudication
processes to be implemented by the USADA.
Compared to the $3.05 million per year the
USOC spends on its anti-doping program, the
Task Force estimates that the initial annual
budget for the USADA will be at least $6
million per year.45  This budget would include
but not be limited to: research and development
(estimated to be at $2 million per year),
collection and testing (estimated at $2.4 million
for 6,000 - 8,000 tests per year), salaries, legal
and consulting fees, Board compensation,
liability insurance and overhead.46  The
USADA, in cooperation with the USOC, will
pursue federal and sponsorship funding to
support additional research.47  Initial funding
from the federal government ($3 million) and
the USOC ($3.7 million) already has been
secured.48  Future funding sources have yet to be
determined.
The Court of Arbitration for Sport (CAS)
The main arbitrating body for doping disputes in
international sports is the Court of Arbitration
for Sport (CAS), established by the IOC in
1983.49  Although the sports community
submitted cases to the CAS, there was concern
that its close association with the IOC
compromised its independence.  To provide a
greater degree of independence for the CAS, the
IOC, along with the International Federations
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and the National Olympic Committees, created
the International Council of Arbitration for Sport
(ICAS) in 1993.50
The International Council of Arbitration for
Sport is a 20-member council, composed of
jurists appointed for a renewable period of four
years.  The ICAS appoints CAS arbitrators.  The
IOC appoints 20 percent of the ICAS members.
The IOC has no direct authority to appoint CAS
arbitrators, but maintains some influence by its
appointment of ICAS members and by its
proposal of CAS arbitrators.51
The CAS Code also provides International
Federations limited influence to select
International Council of Arbitration for Sport
members and to propose CAS arbitrators.
Several International Federations have amended
their statues to establish the CAS rather than
themselves, as the exclusive, final tribunal for
appeal, and all International Federations have
agreed to submit doping disputes to the CAS.
This prevents an International Federation from
acting as both prosecutor and judge in the same
case.52
The International Council of Arbitration for
Sport, rather than the IOC, now oversees the
administration and financing of the CAS, but
many of the procedural rules remain unchanged.
The most important difference is that the IOC no
longer has direct operational control of the
CAS.53
Arbitration, as an alternative to litigation, offers
two major advantages to athletes.  First,
arbitration is typically less expensive that
litigation, making dispute resolution available to
a greater number of athletes.  Second, arbitration
generally provides quicker resolution of disputes
than litigation.  Because elite athletes generally
have short careers, even minimal suspensions
can have major consequences.  For example,
athletes may lose their only opportunity to
participate in the Olympic Games during a
suspension period or may find that they are
unable to compete at their previous skill level at
the end of a suspension period.  Further, the
suspension period may end before a court
resolves the dispute, making the lawsuit moot.
Although an athlete may pursue a subsequent
damage claim, courts may be unable to ascertain
damages with any degree of certainty.  Thus,
CAS arbitration could allow an athlete who
prevails in a dispute an expeditious return to
competition.54
A system of dispute resolution that is fair,
inexpensive and fast benefits Olympic athletes.
The CAS may provide a less expensive and
more expedient choice for dispute resolution in
Olympic sport, but its widespread use depends
on athletes' informed consent to CAS
jurisdiction and their belief that the system is
fair.  As a result of the secretive nature of these
proceedings--the general unavailability of
information due to closed-door hearings and
unpublished decisions--some athletes may fear
that the CAS is unpredictable and inconsistent.*
55
The Athletes' Response
According to a former world record holder in the
marathon, "regulating authorities in the sports
world and the public need to recognize what all
athletes striving to be their best have learned
early in their careers--that everything they do to
prepare for competition is with the hope that it
will enhance their performance."56  In this age of
information and technology, athletes are very
knowledgeable about every conceivable means
of performance-enhancement that are available.
They know exactly what their peers are doing to
prepare for competition--and what seems to be
the most successful.  Whether they indulge in
such practices, they are equally aware of
nonlegitimate practices such as doping.57
* See Appendix D for a summary description of "The
Necessary Components of an Anti-Doping Agency or
Program" from The Duke Conference on Doping in
Sport held May 7-8, 1999 at The Center for Sports
Law and Policy, Duke University School of Law.
I want testing.  It's a pain in the neck but it's
not anything like having a dirty Olympics.58
--Richard Quick, Head Coach
U.S. Olympic Swimming Team
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In general, athletes fall into one of three
categories in their perspective on doping.  At
one end of the spectrum, there is the group that
has no values that conflict with doing whatever
it takes to succeed, whether it is within the rules
or not.  These individuals see doping as a
legitimate means to an end, and justify doping
on any of a variety of different grounds.  At the
other far end of the spectrum are those athletes
who will not engage in any conduct outside of
the rules or that they consider unethical or
unfair.  These athletes would rather lose than
succeed by what they consider to be cheating.59
Within both of these extreme groups, any form
of intervention is unlikely to effect any
substantive difference in athlete behavior.
In the middle are athletes who may have tried,
perhaps for years, to compete within the rules
but have become frustrated at the apparent ease
with which cheaters beat the system.  Many feel
that National Governing Bodies and regulating
authorities are not doing everything possible to
stamp out doping, but are merely making a
public relations effort to appear to do so.  They
may believe that those authorities are more
driven to protect the image of their respective
sport and the money flowing into that sport from
corporate sponsors than to solve the doping
problem.  Eventually, they may concede that
they have no choice but to dope if they are to
remain competitive.61
Throughout the prior decade, several athletes
have attempted to take the initiative in
addressing doping in sport:
• In 1990, German decathletes demanded
regular doping tests.  In 1993, they formed a
"Decathalon Team" independent of their
sports officials, sought their own sponsors,
and promulgated a doctrine of drug-free
sport.  Together with Dr. Manfred Donike,
they developed a pilot project for steroid
profiling.62
• In 1990, German high jumper Dietmar
Mogenburg called for steroid profiling.63
• In 1994, more than 100 French athletes sent
a letter to IOC President, Juan Antonio
Samaranch, asking for action in regards to
the threat presented by traffickers involved
in the black market for steroids.  To date, the
IOC has neither investigated nor protested
the systematic diversion of large quantities
of synthetic hormones to the black market
that makes doping possible.64
• In 1995, members of the international
swimming community called for the
suspension of entire teams if multiple
athletes from a single country were found to
have engaged in doping within a single
year.65
• In 1997, German athletes' representatives
demanded the consistent application of anti-
doping rules following the misbehavior of
Greek athletes and coaches vis-a-vis an
International Amateur Athletic Federation
(IAAF) drug inspector that was ignored by
the IAAF and the IOC.66
• Following the discovery of repeated doping
infractions by Chinese swimmers in 1998,
World Swimming Coaches' Association
members, John Leonard (United States) and
Forbes Carlile (Australia), publicly stated
that investigations done by the international
federation for swimming, (i.e., the
Federation Internationale de Natation
Amateur) into doping charges against
members of the Chinese and German
championship teams, were merely "an
exercise in damage control."  Further, they
called for a "thorough investigation of
China's swimming program by a panel of
independent experts."67
I'd like to know he's been tested...I bet he
would like to know I've been tested.  It's
something that makes you feel the playing
field is even.60
--Ed Moses
U.S. Olympic Swimmer
-51-
• In March 1999, the representative of the
German swimmers, Chris-Carol Bremer,
called for state intervention against doping.
Further, German swimmer Sandra Volker
publicly expressed a lack of confidence in
the official anti-doping campaign and called
for the introduction of blood tests.68
• In October 1999, the athlete organization,
Olympic Advocates Together Honourably
(OATH), released a report stating that "new
doping control measures must be rooted in
sport ethics and values; flow from athlete
agreement; and be independently,
accountably, and fairly administered."70
They articulated that the fight against doping
is international--requiring cooperation and
partnerships--and that anti-doping efforts
require an international anti-doping agency.
Toward that end, the IOC must "go to the
experts to create this anti-doping agency"
and "be prepared to relinquish control of the
new agency in order to secure independence
and a genuine international partnership."71
The IOC Athletes' Commission, responsible for
acting as the mediator between Olympic athletes
and the IOC, has recommended the adoption of
"doping passports."  Such a passport would be
an accessible and public history of an athlete's
doping tests, including health history, hormone
levels, hematocrit and other relevant data.72
While concerns undoubtedly will be raised about
athlete privacy and confidentiality, doping
passports could rectify the situation of athletes
who are unfairly penalized for having natural
hormone or other biochemical levels outside the
range of what is considered normal (e.g.,
athletes who naturally have a hematocrit over
50).  Passports also would provide the type of
open record necessary to help restore the
integrity of sport.
The fact that athlete initiatives such as these
appear to have been ignored adds to athletes'
perceptions of passivity and complicity on the
part of Olympic and federation officials.  Athlete
initiatives alone have not worked, perhaps,
because the elite athlete population is too young,
too transient or too disorganized.73  As one elite
athlete has stated, "We athletes are all solitary
figures.  We lack a charismatic leader, a
spokesperson who is fighting for our cause and
unifying many voices.  And we don't
communicate with each other."74
You'd have to be an imbecile or a hypocrite
to imagine that a professional cyclist who
rides 235 days a year can hold himself
together without stimulants.69
--Jacques Anquetil (1967)
Five-time Tour winner
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Chapter VI
Recommendations and Next Steps
To protect the health of athletes and the children
who model their behavior and the integrity of
Olympic sports, doping practices must be
removed from Olympic competition.  The
evidence is clear: many performance-enhancing
substances can cause serious harm when used in
the methods and levels designed to provide
competitive advantage.  For too many
substances, we simply do not know the long-
term consequences of their use, and substances
that seem safe for adults may be dangerous to
youth.
The Olympic Games have come to be viewed as
the pinnacle of modern sport.  The thousands of
participating athletes, coaches and officials, and
a vast international audience bear witness to the
prestige and popularity of the games and help us
understand the powerful hold of sports on the
public's imagination.  As captured by the
Olympic motto "Citius, altius, fortius" (swifter,
higher, stronger), ideally the Olympic athletes
portray some of the more poignant examples of
triumphs of the human spirit.  While the use of
performance-enhancing substances in sport has
existed since the origins of sport itself, today the
size and magnitude of doping practices and the
disincentives to curb such practices threaten to
destroy the integrity of the Olympic games.
Some believe that this time has already come.
Because the stakes are so high for all involved,
no single entity--athletes, coaches and trainers,
Governing Bodies, corporate sponsors--has been
able to break the thrall of doping.  Getting
If we will have reached a point of no return
with this win at all costs attitude, the gold
medals won't shine as brightly, the flags won't
wave as boldly, the torch will flicker dimly,
and we will have lost one of the greatest
treasures ever known.1
--Robert Voy, MD
Former USOC Director of
Doping Control Administration
®
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doping out of sports will require the political
will of all involved.  National governments must
demand change and the creation of needed
standards and systems to restore integrity to
Olympic sports.
The CASA National Commission on Sports and
Substance Abuse presents the following
roadmap:
• Participant nations--and the other key
players--should demand that Olympic
level athletes be free of performance-
enhancing substances.  Nations must
garner the political will to act in order to
protect the health of athletes, preserve the
integrity of sport and send positive messages
to children.  They must lead the way to build
support for getting doping out of sports.
Parents who organize and promote athletic
events for their children should send clear
messages against doping in sports.  Current
and former Olympic athletes should be
enlisted to demand and support anti-doping
policies.  Coaches and trainers should set
anti-doping standards and reinforce them
with positive messages of substance-free
competition.  Corporate sponsors should
show leadership by championing drug-free
sports and by demanding that athletes be
substance-free for the games they sponsor.
Public support exists in the United States for
this position.  Americans disapprove of the
use of performance-enhancing drugs by
athletes and view these substances as health
hazards.  Nearly as many young Americans
(83 percent) disapprove of such drug use as
adults (86 percent).2  Among those age 12
to18, 73 percent say that young people are
harming themselves or running the risk of
damaging their health when they take
performance-enhancing drugs.  A 77 percent
majority of adults agree that Olympic
sponsors should become more involved in
reforming the Olympic movement and 76
percent say that Congress should take steps
to make sure that athletes who compete in
the 2002 Salt Lake Winter Games are drug-
free.3
• Participant nations should ensure that an
independent international organization
exists with authority over the methods of
measurement and sanctions for doping in
Olympic sports.  This organization would
not report to the IOC or any sport governing
body.  It would have responsibility over the
types of substances to ban; the types of tests
to be conducted; the timing of those tests,
the sample collection, analysis and reporting
processes; adjudication referral and
adjudication.  This organization should
develop consistent standards for the
detection of performance-enhancing
substances and sanctions for their use, and
assure consistent use of these standards and
sanctions throughout the Olympic
movement.  The IOC should commit a
percentage of its overall budget to support
this effort.
• Conduct research needed to determine
long-term consequences of use of
performance-enhancing substances.
Priorities for research to determine the long-
term consequences of performance-
enhancing substances include:  the health
effects of products that are sold as
nutritional supplements, especially
androstenedione, creatine and ephedrine;
and the efficacy and long-term effects of
steroid use, including precursor substances.
• Expand and improve cost-effective
testing.  Priorities to expand and improve
cost effective testing include: an
international collaborative effort, funded
over a five-year period at a total of at least
$50 million to $100 million, to find and
develop reliable tests to detect the use of the
major performance-enhancing drugs;
inexpensive testing procedures for steroids;
cost-effective methods to detect use of
human growth hormone (hGH) and insulin-
like growth factor (IGF-1); and methods of
keeping pace with the development of new
drugs as they emerge.  Testing should be
done on the basis of the best available
technology, whether it is a test for a
substance in the urine, blood, hair, sweat or
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oral fluids or is a test of the performance-
enhancing effects of a substance.  Research
should be peer-reviewed to assure credibility
and increase acceptability in the
adjudication process.
• Conduct comprehensive out-of-
competition testing.  Comprehensive out-
of-competition testing is essential to an
effective doping program.  Event or in-
competition testing is useful for detecting
substances that provide relatively fast-acting
performance benefits for the user (e.g.,
stimulants to delay or reduce fatigue).
However, many substances provide the
greatest benefits to athletes when used
during training (e.g., steroids to increase
muscle mass).  If only in-competition testing
is used, athletes may cease using a banned
substance in sufficient time to clear its
metabolites from their systems.  The only
way to detect use of these banned training
drugs is through a no-advance notice, out-
of-competition testing program.
• In the United States, strengthen the
provisions of the Dietary Supplement
Health and Education Act of 1994.
Athletes claim that they may unknowingly
take banned substances in unlabeled or
poorly labeled nutritional supplements.
Congress should require manufacturers of
dietary supplements to identify all contents
and to label their products accurately.
Concerns about youth mimicking athletes'
behavior and ingesting substances which
may be harmful or for which long-term
effects are unknown provide another reason
for Congress to act.  Any claims of results
now permitted under the Act related to
structure and function should be supported
by peer-reviewed research.  Congress should
consider regulating testosterone precursors
as drugs rather than as nutritional
supplements.
• Adopt Athlete Passports.  A "doping
passport"* 4 is an accessible and public
history of an athlete's doping tests.5  Health
histories of athletes, with hormone levels,
hematocrits and other data spanning several
years can be incorporated into this
document.6  Such a passport could rectify
the situation of athletes who are unfairly
penalized for having natural hormone or
other biochemical levels outside the range of
what is considered normal (e.g., athletes
who naturally have a hematocrit over 50).
Publically available passports would provide
the type of open record necessary to help
restore the integrity of sport.
• Adopt a standard protocol for
establishing the banned substances list.
To determine which substances to ban in
Olympic competition, an independent
organization should adopt an open and
public process based on current scientific
evidence and grounded in consistently
applied rules.  This process should be
applied to new candidate substances as they
are developed  and eventually to the current
list of banned substances in order to identify
those to be added or removed. (Appendix E)
Any framework for making these decisions
must be grounded in the IOC's basic
philosophy that the use of these drugs is
contrary to the fundamental principles of
Olympic competition, sports and medical
ethics, using its current definition of doping
as the starting point.†  A specific substance
should undergo the following levels of
analyses:  (1) Is the use of this substance
associated with severe adverse effects, life-
threatening illness, or premature death?
* Proposed by the IOC Athletes Commission which is
responsible for acting as the mediator between active
Olympic athletes and the IOC.
† As of January 1, 2000, doping is defined as:  (1) the
use of an expedient (substance or method) which is
potentially harmful to athletes' health and/or capable
of enhancing their performance, or (2) the presence in
the athlete's body of a Prohibited Substance or
evidence of the use thereof or evidence of the use of a
Prohibited Method.
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(2) Does use of this substance enhance
athletic performance?  (3) Can this
substance be used as a masking agent?  If
the answer to any of these question is yes,
the substance would be banned.
If a substance is banned, the next question is
whether or not there is a reliable, valid and
affordable test for this substance or method.
If not, research needs should be identified
and enforcement based on observation of
use.  If a test is available, enforcement
should be based on testing and observation.
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Appendix B
Summary of Drug Testing Regulations
League: US Olympic Committee/International Olympic Committee
US Olympic Committee Drug Control Administration
International Olympic Committee Doping Control Program 
______________________________________________________________________________
In-Competition Testing Program YES
Out-of-Competition Testing Program YES
No Advance Notice Testing Program YES
Selection Criteria for Testing All sports are subject to testing.  The IOC
Medical Commission, with the cooperation of
the International Federation concerned and the
Organizing Committee, decide the number of
competitors to be subjected to testing per day in
each sport.  The capacity of the laboratory is
given due consideration.  In general, testing will
include the first four competitors in the final
classification and others chosen at random.
The USOC, in cooperation with national sports
governing bodies, follows similar parameters for
in-competition testing and randomly selects
athletes from an eligible pool for No Advance
Notice testing.
Substances Specifically Banned See Appendix B (Olympic Movement Anti-
Doping Code) for specific substances.
Prohibited classes of substances include:
stimulants, narcotics, anabolic agents, diuretics,
marijuana, and peptide and glycoprotein
hormones and analogues.  Blood doping and
pharmacological, chemical, and physical
manipulation of urine is prohibited.  Drugs
subject to certain restrictions include: alcohol,
local anesthetics, corticosteroids, and beta-
blockers.
_____________________________________________________________________________________
Penalty for First Infraction In compliance with due process requirements
and procedures, disqualification if the infraction
occurred during competition, plus:
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a) In cases of a positive result for ephedrine,
phenylpropanololamine, pseudoephedrine,
caffeine, strychnine and related compounds,
a maximum suspension of three months.
b) Except in the cases covered by (a) above, a
suspension from all competition for two
years.
If such competitor is a member of a team, the
match during which the infraction took place
shall be considered forfeited by that team.
Penalty for Second Infraction a)   In cases involving ephedrine,
phenylpropanolamine, pseudoephedrine,
caffeine, strychnine, and related compounds,
disqualification if the infraction occurred during
a competition plus a two year suspension.
b)   Except those cases described in (a),
disqualification if the infraction occurred during
a competition plus a lifetime suspension from all
Olympic competition.
Penalty for Third (+) Infraction a)   In cases involving ephedrine,
phenylpropanolamine, pseudoephedrine,
caffeine, strychnine, and related compounds,
lifetime suspension from all Olympic
competition.
b)   Not applicable in all other cases.
_____________________________________________________________________________________
Possibility for Reinstatement Not specified.
Criteria for Reinstatement Not specified.
_____________________________________________________________________________________
Treatment Options Not specified.
The USOC has a drug reference line and
education services available for athletes,
administrators, coaches, trainers, and other
involved parties.
______________________________________________________________________________
Other Considerations The USOC cooperates with a variable number of
other countries through the mechanism of bi-
lateral (or multi-lateral) drug control
agreements.  It also cooperates with the National
Collegiate Athletic Association (NCAA) and the
National Football League (NFL) in an on-going
joint research funding venture.
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League: International Amateur Athletic Federation
_____________________________________________________________________________________
In-Competition Testing Program YES
Out-of-Competition Testing Program YES
No Advance Notice Testing Program YES
Selection Criteria for Testing In-Competition:
Selection is generally on a final position and/or
random basis.  Selection of further athletes may
be ordered at the discretion of the IAAF, the
doping Control Official, or the Doping Delegate
by any method that it or he/she chooses.  Testing
will also be conducted on any athlete who is
deemed to have broken or equaled an Area or
World Record.
Out-of-Competition:
Individual or groups of athletes may be tested at
the discretion of the IAAF.
Substances Specifically Banned Prohibited classes of substances include:
anabolic agents; amphetamines; peptides,
glycoprotein hormones and analogues; cocaine;
other stimulants; and narcotic analgesics.
Prohibited methods include use of blood doping
(e.g. erythropoietin) and urine manipulation
techniques (e.g. diuretics, probenecid,
bromantan, etc.).
_____________________________________________________________________________________
Penalty for First Infraction Player ineligible for a minimum of two years for
infractions involving the use of anabolic agents
(androgenic anabolic steroids, beta-2-agonists);
amphetamines; peptide, glycoprotein, and
glucocorticosteroid hormones and analogues;
cocaine; and prohibited techniques (blood
doping, erythropoetin, epitestosterone).
Player given a public warning and is disqualified
from the competition at which the sample was
collected for infractions involving the use of
sympathomimetic amines and narcotic
analgesics.
Penalty for Second Infraction Player ineligible for life for infractions involving
the use of anabolic agents (androgenic anabolic
steroids, beta-2-agonists); amphetamines;
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peptide, glycoprotein, and glucocorticosteroid
hormones and analogues; cocaine; and
prohibited techniques (blood doping,
erythropoetin, epitestosterone).
Player ineligible for two years (from the date of
provision of the sample) for infractions
involving the use of sympathomimetic amines
and narcotic analgesics.
Penalty for Third (+) Infraction Player ineligible for life for infractions involving
the use of sympathomimetic amines and narcotic
analgesics.
_____________________________________________________________________________________
Possibility for Reinstatement YES for time-specified periods of ineligibility.
NO for lifetime ineligibility.
Criteria for Reinstatement Once an athlete’s period of ineligibility has
expired, he/she will become automatically re-
eligible provided:
a) He/she has tested negatively for out-of-
competition testing conducted at any time
during the period of ineligibility and
immediately prior to the end of the
suspension period; if suspension was for two
years or more, athlete must also test negative
for a minimum of three tests during this
period with at least four months between
each test.
b) He/she has made satisfactory report on the
circumstances surrounding the doping
offense to his/her National Federation.
c) The appropriate National Federation has
submitted its report on the case to the IAAF.
_____________________________________________________________________________________
Treatment Options None specified.
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League: International Cycling Union/Union Cycliste Internationale
_____________________________________________________________________________________
In-Competition Testing Program YES
Out-of-Competition Testing Program YES
No Advance Notice Testing Program YES
Selection Criteria for Testing **Testing criteria differ depending on type of
race
Mandatory at the following events:
a) World Championships, Continental
Championships and Regional Games
b) World record and continental record
attempts
c) Any other event of the world and continental
calendars designated by the Antidoping
Commission
The UCI Antidoping Commission, for each
event, instructs the Inspector to select up to 10
riders to be tested.
When no such instructions are issued, the
following riders shall be tested:
I) One-Day events (all disciplines):
a) General Rule:
1) First rider placed
2) Two riders selected at random
b) Half-stages:
1) First rider placed in the first
half-stage
2) First rider placed in the second
half-stage
3) A rider selected at random from
each half-stage
c) Team events:
1) Rider selected at random from
the first place team
2) Two riders selected at random
from all other teams
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II) Stage events (all disciplines, including
prologue):
a) General Rule:
1) First rider placed in the stage
2) First rider in the general
classification after the stage
3) Two riders selected at random
b) Team Time Trial stage:
1) Rider selected at random from
the first team placed
2) First rider in the general
classification after the stage
3) Two riders selected at random
from all other teams
c) Half-stage:
1) First rider placed in the first
half-stage
2) First rider placed in the second
half-stage
3) First rider in the general
classification after the second
half-stage
III) Specific Time-trial events:
a) Individual:
1) First three riders placed
2) Two riders selected at random
b) Team:
1) One rider selected at random
from the first team placed
2) One rider selected at random
from the second team placed
3) One rider selected at random
from each of four other different
teams selected at random
IV) Track events (all disciplines):
a) Individual:
1) First rider placed
2) Three riders selected at random
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b) Team:
1) One rider seleted at random for
the first team placed
2) Three riders selected at random
from all the other teams
V) Six-day events:
a) One rider selected at random from
the team placed first
b) Three riders selected at random
from various other teams
Substances Specifically Banned Prohibited classes of substances include:
stimulants, narcotics, anabolic agents
(androgenic anabolic steroids and nonsteroidal
anabolic agents), masking agents and peptide
hormones and analogues.  Blood doping and
pharmacological, chemical or physical
manipulation are prohibited as well.
Corticosteroids and local anaesthetics are subject
to certain restrictions.  Marijuana is prohibited in
the "downhill" mountain bike discipline at levels
exceeding 40 nanograms/milliliter.
_____________________________________________________________________________________
Penalty for First Infraction **Disciplinary measures vary by level of
competition and gender.
I) Elites:
a) Men:
1) Disqualification and suspension
for six months minimum to one
year maximum
2) Fine of SFr. 2,000 minimum to
SFr. 4,000 maximum
3) Loss of 50 points in individual
classification
b) Women:
1) Disqualification and suspension
for six months minimum to one
year maximum
2) Fine of SFr. 1,000 minimum to
SFr. 2,000 maximum
3) Loss of 20 points in individual
classification
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II) Under 23:
a) Disqualification and suspension for
six months minimum to one year
maximum
b) Fine of SFr. 500 minimum to SFr.
1000 maximum
c) Loss of 20 points in individual
classification
III) Other riders:
a) Disqualification and suspension for
six months minimum to one year
maximum
Penalty for Second Infraction I) Elites:
a) Men:
1) Disqualification and suspension
for one year minimum to two
years maximum
2) Fine of SFr. 4,000 minimum to
SFr. 6,000 maximum
3) Loss of 75 points in individual
classification
b) Women:
1) Disqualification and suspension
for one year minimum to two
years maximum
2) Fine of SFr. 3,000 minimum to
SFr. 5,000 maximum
3) Loss of 30 points in individual
classification
II) Under 23:
a) Disqualification and suspension for
one year minimum to two years
maximum
b) Fine of SFr. 1,500 minimum to SFr.
3,000 maximum
c) Loss of 20 points in individual
classification
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III) Other riders:
a) Disqualification and suspension for
one year minimum to two years
maximum
Penalty for Third (+) Infraction I) Elites:
a) Men:
1) Disqualification and permanent
debarment
2) Fine of SFr. 8,000
b) Women:
1) Disqualification and permanent
debarment
2) Fine of SFr. 8,000
II) Under 23:
a) Disqualification and permanent
debarment
b) Fine of SFr. 8,000
III) Other riders:
a) Disqualification and permanent
debarment
_____________________________________________________________________________________
Possibility for Reinstatement None specified.
Criteria for Reinstatement None specified.
_____________________________________________________________________________________
Treatment Options None specified.
_____________________________________________________________________________________
Other Considerations For team events, a positive test for a single rider
will result in the disqualification of the entire
team.
Special sections on the list of doping agents
carry distinct penalties (refer to text on UCI
antidoping regulations).
A first offense is committed after a three-year
offense-free period where an offense is defined
to be a positive result, fraud, or an attempted
fraud.
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A second offense shall be deemed to be
committed if within a three-year period
following the first.
A third offense shall be any offense committed
after two other offenses, regardless of the period
that may have elapsed between them.
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League: U.S. Soccer Federation/Federation Internationale de Football
Association (FIFA)
_____________________________________________________________________________________
In-Competition Testing Program YES
Out-of-Competition Testing Program YES
No Advance Notice Testing Program NO
Selection Criteria for Testing Two players from each team in every match in
which doping tests are to be carried out are
randomly selected for testing.
In 1998 World Cup Competition (France), for
each match, four players were selected randomly
for possible testing but only the first two players
were actually tested.  The remaining two players
were tested only in cases of injury to either of
the first two players.  These selection procedures
may change with the next World Cup
competition.
Reasonable cause as determined by FIFA
Commissioner and/or referee of the match.
Substances Specifically Banned Classes of substances prohibited include:
stimulants, narcotic analgesics, anabolic
steroids, diuretics, peptide and glycoprotein
hormones and related substances.  Blood doping
and pharmacological, chemical and physical
manipulation methods are also prohibited.
Substances subject to partial restriction include:
alcohol, beta blockers, local anesthesthetics, and
corticosteroids.
_____________________________________________________________________________________
Penalty for First Infraction Determined by Organizing Committee; dealt
with on a case-by-case basis.
Penalty for Second Infraction Determined by Organizing Committee; dealt
with on a case-by-case basis.
Penalty for Third (+) Infraction Determined by Organizing Committee; dealt
with on a case-by-case basis.
___________________________________________________________________________________
Possibility for Reinstatement None specified.
Criteria for Reinstatement None specified.
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Treatment Options None specified.  Drug Education program being
considered.
____________________________________________________________________________________
Other Considerations Matters not provided for in the regulations shall
be decided by the Organizing Committee.
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Appendix B
Olympic Movement Anti-Doping Code
Prohibited Classes of Substances and Prohibited Methods
April 1, 2000
I. Prohibited Classes of Substances
A. Stimulants - Prohibited substances in class (A) include the following examples:  amineptine,
amiphenazole, amphetamines, bromantan, caffeine,* carphedon, cocaine, ephedrines,** fencamfamin,
mesocarb, pentetrazol, pipradrol, salbutamol,*** salmeterol, terbutaline and related substances.
NOTE:  All imidazole preparations are acceptable for topical use.  Vasoconstrictors may be
administered with local anaesthetic agents.  Topical preparations (e.g., nasal, ophthalmological,
rectal) of adrenaline and phenylephrine are permitted.
* For caffeine, the definition of a positive is a concentration in urine greater than 12 micrograms per millilitre.
** For cathine, the definition of a positive is a concentration in urine greater than 5 micrograms per millilitre.  For
ephedrine and methylephedrine, the definition of a positive is a concentration in urine greater than 10 micrograms
per millilitre.  For phenylpropanolamine and pseudoephedrine, the definition of a positive is a concentration in urine
greater than 25 micrograms per millilitre.
*** Permitted by inhaler only to prevent and/or treat asthma and exercise-induced asthma.  Written notification of
asthma and/or exercise-induced asthma by a respiratory or team physician is necessary to the relevant medical
authority.
B. Narcotics - Prohibited substances in class (B) include the following examples:  buprenorphine,
dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine and related
substances.
NOTE:  Codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate,
ethylmorphine, pholcodine, propoxyphene and tramadol are permitted.
C. Anabolic agents - Prohibited substances in class (C) include the following examples:
1. Anabolic androgenic steroids
a. clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol,
19-norandrostenedione, oxandrolone, stanozolol and related substances
b. androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone,
testosterone,* and related substances.
Evidence obtained from metabolic profiles and/or isotropic ratio measurements may be used to
draw definitive conclusions.
*  The presence of testosterone (T) to epitestosterone (E) ratio greater than six (6) to one (1) in the urine of
a competitor constitutes an offense unless there is evidence that this ratio is due to a physiological or
pathological condition, e.g., low epitestosterone excretion, androgen producing tumor, enzyme deficiencies.
In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an
investigation before the sample is declared positive.  A full report will be written and will include a review
of previous tests, subsequent tests and any results of endocrine investigations.  In the event that previous
tests are not available, the athlete should be tested unannounced at least once per month for three months.
The results of these investigations should be included in the report.  Failure to cooperate in the
investigations will result in declaring the sample positive.
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2. Beta-2 agonists - bambuterol, clenbuterol, fenoterol, formoterol, reproterol, salbutamol,*
salmeterol,* terbutaline* and related substances.
* Authorized by inhalation as described in Article (I.A.).
For salbutamol, the definition of a positive under the anabolic agent category is a concentration in
urine greater than 1000 nanograms per millilitre.
D. Diuretics - Prohibited substances in class (D) include the following examples:  acetazolamide,
bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannitol,* mersalyl,
spironolactone, triamterene and related substances.
* Prohibited by intravenous injection.
E. Peptide hormones, mimetics and analogues - Prohibited substances in class (E) include the following
examples and their analogues and mimetics:
1. Chorionic Gonadotrophin (hCG) prohibited in males only;
2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only;
3. Corticotrophins (ACTH, tetracosactide);
4. Growth hormone (hGH);
5. Insulin-like Growth Factor (IGF-1);
and all the respective releasing factors and their analogues;
6. Erythropoietin (EPO);
7. Insulin;
permitted only to treat athletes with certified insulin-dependent diabetes.  Written
certification of insulin-dependent diabetes must be obtained from an endocrinologist or team
physician.
The presence of an abnormal concentration of an endogenous hormone in class (E) or its
diagnostice marker(s) in the urine of a competitor constitutes an offense unless it has been
proven to be due to a physiological or pathological condition.
II. Prohibited Methods
The following are prohibited:
1. Blood doping;
2. Adminstering artificial oxygen carriers or plasma expanders;
3. Pharmacological, chemical and physical manipulation.
III. Classes of Prohibited Substances in Certain Circumstances
A. Alcohol - Where the rules of a responsible authority so provide, tests will be conducted for ethanol.
B. Cannabinoids - Where the rules of a responsible authority so provide, tests will be conducted for
cannabinoids (e.g., Marijuana, Hashish).  At the Olympic Games, tests will be conducted for
cannabinoids.  A concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid
(carboxy-THC) greater than 15 nanograms per millilitre constitutes doping.
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C. Local anaesthetics - Injectable local anaesthetics are permitted under the following conditions:
a. bupivacaine, lidocaine, mepivacaine, procaine and related substances, can be used but not
cocaine.  Vasoconstrictor agents may be used in conjunction with local anaesthetics;
b. only local or intra-articular injections may be administered;
c. only when medically justified.
Where the rules of a responsible authority so provide, notification of administration may be
necessary.
D. Glucocorticosteroids -  The systemic use of glucocorticosteroids is prohibited when administered
orally, rectally or by intravenous or intramuscular injection.
E. Beta-blockers -  Prohibited substances in class (E) include the following examples:  acebutolol,
alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, propranolol, sotalol and related
substances.
Where the rules of a responsible authority so provide, tests will be conducted for beta-blockers.
Summary of Urinary Concentrations Above Which
IOC Accredited Laboratories Must Report Findings for Specific Substances
caffeine > 12 micrograms/millilitre
carboxy-THC > 15 nanograms/millilitre
cathine > 5 micrograms/millilitre
ephedrine > 10 micrograms/millilitre
epitestosterone > 200 nanograms/millilitre
methylephedrine > 10 micrograms/millilitre
morphine > 1 microgram/millilitre
19-norandrosterone > 2 nanograms/millilitre in males
19-norandrosterone > 5 nanograms/millilitre in females
phenylpropanolamine > 25 micrograms/millilitre
pseudoephedrine > 25 micrograms/millilitre
salbutamol
  (as stimulant) > 10 nanograms/millilitre
  (as anabolic agent) > 1000 nanograms/millilitre
T/E ratio > 6
IV. Out-of-Competition Testing
Unless specifically requested by the responsible authority, out-of-competition testing is directed
solely at prohibited substances in class I.C. (Anabolic Agents), I.D. (Diuretics), I.E. (Peptide
Hormones, Mimetics and Analogues) and II (Prohibited Methods).
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Appendix C
Recommended Adjudication Process for the USADA as
Delineated by The USOC Select Task Force on Drug Externalization*
1. The United States Anti-Doping Agency (USADA) shall notify the athlete of an adverse finding or a
presumed positive of the A sample.  Notification should include the name(s) and quantity of the
detected substance(s).  The athlete or his/her representative will have the opportunity to attend the
analysis of the B sample.
2. In cases of an adverse finding, e.g., elevated Testosterone/Epitestosterone ("T/E") ratio, the USADA
shall conduct any further investigation and make a determination confirming the test.
3. The USADA shall commence a doping related infraction case upon any one of the following
circumstances: a confirmed adverse finding or presumed positive (B confirmation of the A sample),
an athlete's refusal or failure to comply with a doping control test, a written admission of a doping
infraction, or a request for a determination based upon evidence of a doping infraction made by a
recognized sport organization (such as a national or international sport governing body, a major sports
organization or the national anti-doping organization of another country),  Upon commencement of a
case, the USADA shall immediately notify the athlete of the particulars of the infraction by certified
letter, overnight delivery service with a signed receipt or by personal service.
4. Upon commencement of a case, the USADA shall convene a panel of three impartial individuals (the
"Review Panel") to review evidence of a doping related infraction and to make a determination as to
whether there is probable cause for a finding of a doping related infraction.  This review shall be done
in the strictest confidence.  The USADA shall develop and maintain a list of impartial individuals
who are expert in the field of drug testing, sport science, medicine, legal matters and ethics who shall
be available to serve on the Review Panel.  The Review Panel shall be paid on a per case basis.
5. The standard documentation package shall be furnished to the Review Panel for its review.  This
information shall also be furnished to the athlete.  The Review Panel may request additional material
if it determines that such material would be helpful to it in its deliberations.  The athlete may submit a
written statement to the Review Panel, but shall have no right to otherwise appear before or
participate in the Review Panel's deliberations.
6. The Review Panel shall either find probable cause that a doping related infraction has occurred or that
the case be closed and no further action be taken.  All decisions of the Review Panel shall be by
majority vote.  The Review Panel shall inform the USADA and the athlete of its decision in writing.
This finding shall not be admitted into evidence in any subsequent hearing.
7. Upon a finding of probable cause, the athlete may either admit the doping infraction or deny the
doping infraction.  If the doping infraction is admitted, the USADA will forward the admission,
including the sanction to be imposed, to the USOC, and to the appropriate National Governing Body
(NGB) and International Federation (IF) for action.
8. If the doping infraction is denied, the matter shall be set for a hearing.  A standard documentation
package compiled by the testing laboratory shall immediately be forwarded to all participating
parties.
* Source: Report of the USOC Select Task Force on Drug Externalization, December 3, 1999.
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9. The USADA shall prosecute all doping infraction cases.
10. The American Arbitration Association (AAA), in conjunction with the local arm of the Court of
Arbitration for Sport (CAS), shall be responsible for the administration of doping infraction hearings
in the United States.  The AAA and CAS shall develop a process for the administration of doping
infraction cases that satisfies both organizations.  The AAA and CAS shall establish a pool of
arbitrators that is approved by both organizations.  The AAA/CAS shall be responsible for setting
hearing dates and locations.  The AAA/CAS shall make provisions for having an expedited hearing
process.
11. Three arbitrators (the "Hearing Panel") shall be empanelled to hear each case.  Selection of the
arbitrators shall be conducted in such a way so as to provide for agreement of the parties on the
arbitrators or for the opportunity to strike arbitrators.  The Hearing Panel shall decide all issues
relating to discovery, motions and other procedural matters.  The Hearing Panel may, on its own
initiative, appoint a scientific expert as a "friend of the court."
12. In all cases, the USOC and the NGB shall be bound by the determination of the hearing panel.
13. The appropriate IF shall be notified of the hearing.  The IF shall be invited to participate in the
hearing.  The IF can appear, but take no part, on behalf of the athlete or on behalf of the USADA.  If
the IF chooses to appear, it shall be bound by the determination of the Hearing Panel.
14. An individual accused of a doping infraction shall be afforded fair notice and an opportunity for a
hearing.  The burden and standard of proof shall be determined by the Hearing Panel upon
consideration of the particulars of the case.  All decisions of the Hearing Panel shall be by majority
vote.
15. The USADA shall maintain confidentiality of all matters pertaining to a positive test or adverse
finding until completion of the hearing process, unless the athlete requests public disclosure.  Upon
completion of the hearing process, all findings shall be made public.  The USADA may issue periodic
public reports indicating the number of positive tests and adverse findings.
16. If the Hearing Panel finds a doping infraction, it will then consider the penalty to be imposed, taking
into consideration the rules of the appropriate NGB and IF.  The Hearing Panel will forward its
decision, including the recommended sanction to be imposed, to the USOC and to the appropriate
NGB and IF for action.
17. The decision of the Hearing Panel shall be communicated to all parties in writing.
18. Any party to the hearing may appeal the Hearing Panel's decision to the CAS, which shall then hear
the case de novo and pursuant to its procedures (a CAS appeal arbitration proceeding).
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Appendix D
Recommendations Addressing Regulatory Issues from Experts
in Athlete Doping Control
In May 1999, the Duke University School of Law released a report that attempted to address the broad
societal concerns regarding athlete drug use, and provide an agenda for organizations that wish to tackle
the issue of drugs in sport.  The conference included experts in the fields of law, ethics, sociology,
education, medicine, and athletics, and members of the affected sports organizations, including athletes
and officials, and their corporate sponsors.  Special emphasis was placed on:  (1) independence and the
structure that independent governance of drug testing programs might take; (2) the science of doping and
doping control; and (3) the legal concerns of accused athletes and governing organizations in maintaining
effective doping control.  The recommendations from this conference reflect the most current independent
expert opinions regarding the necessary legal components of an anti-doping agency or program.  These
recommendations were:
♦ The adjudication process should be entirely independent of the governing bodies.  The governing
bodies should have an educational role, informing athletes of the dangers of doping and of the ethical
foundation of sports.  National governing bodies should not be placed in an adversarial role vis a vis
their athletes in doping cases.
♦ The adjudication process must include the following safeguards: (1) prosecutions will be based on
scientifically determined violations, (2) all prohibited substances must be detectable in the athlete's
urine or body fluids through a method that is scientifically valid, and (3) all prohibited substances
must be banned on the basis of research that takes into consideration such relevant factors as
ethnicity, age, gender, and medical history.
♦ The adjudication process should proceed in three distinct stages:
1) There should be a preliminary review by a panel composed of relevant experts, including physicians,
other scientists, and lawyers.  The purpose of this review is to determine (a) if all procedures were
followed for collection, storage, transportation, and testing of the athlete's sample and, (b) if based on
the laboratory report, the results of the analysis are sufficiently strong evidence of the athlete's guilt.
During this preliminary stage of the proceedings, the identity of the athlete is held strictly
confidential.  If the review panel finds that the published mandatory procedures for the collection,
storage, transportation, and testing of the sample were not strictly followed, it must declare the
sample invalid and end the process.  If the review panel determines that the collection, storage,
transportation, and testing of the sample complied fully with the rules, and that the analysis provides
sufficiently strong evidence of the athlete's guilt, it will forward the case for prosecution.  At that
point, there may be a rebuttable presumption of the athlete's guilt.  The independent anti-doping
agency or program will be responsible for the prosecution of all doping cases. The review panel will
make periodic public reports of the number of cases dismissed in this manner, and the basis for each
dismissal.  The names of the athletes involved will not be disclosed.
2) The determination of whether a doping violation took place must be decided by qualified decision
makers.  There are currently two possible models.  The first is the American Arbitration Association
(AAA).  One of the advantages of the AAA is its familiarity and suitability for emergency disputes.
The second is the International Court of Arbitration for Sport (CAS).  One of the advantages of the
CAS is its potential international acceptance, and thus potential for finality.
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One of the most important criterion for the body ultimately selected to decide the merits of cases
is the employment of adjudicators with experience deciding contested scientific disputes.
There must be regularized procedures for all hearing panels.  Panels must publish all decisions,
and the bases for decision.  If the CAS is used, it would have to establish regional panels to
streamline the process.
There must be a process for providing counsel to athletes accused of a doping violation.  This
might be accomplished through a Judge Advocate General-type structure, which would provide
both the prosecutors and the defense counsel, under the direction of an independent overseer.
Another possibility is the reliance on pro bono counsel.  A third possibility is the use of an
approved list of counsel.  In the end, some combination of these three might be employed.
One issue left unresolved was at what point an athlete should be suspended.  There was
agreement that liability should not attach before a suspicious sample was confirmed by a second
analysis of the sample.  There was some support for this confirming analysis being done by a
different laboratory than the one that performed the initial analysis.  There also was support for
the athlete's early involvement in the preliminary stage of the process, to raise limited compliance
issues before the review panel.  There was not agreement about whether this would constitute a
hearing for purposes of the Amateur Sports Act, which bars a suspension prior to a hearing.
There was agreement that an athlete's certification of the sample collection procedures could be
used against him or her in a contested hearing, although the athlete still could challenge the
collection.  For this reason, one of the important functions of the national governing body would
be the education of its athletes in the process and their rights under the program.
3) The final stage of the process involves proceedings in the athlete's national courts or before
international federations.
There was agreement that a credible and bona fide arbitration process as outlined above would
result in minimizing the role of civil courts.  There was also agreement on the need for
harmonization among the rules of the various federations to which an athlete might be subject.
Any obligation that a national governing body had for doping disputes under the rules of its
international federation would have to be delegated to the independent doping agency.  Thus, a
sample tested outside the United States would be subject to the same preliminary compliance
review that a sample generated in the United States would receive.  And the failure to follow the
requirements for the collection, storage, transportation, and testing of the sample by the foreign
entity would result in the sample being declared invalid.
Appendix E
Proposed Banned Substance Decision Process
Is its use associated with a life-threatening
illness, or premature death?
Does it enhance performance?
ID further
research needed
Conduct research
Provide feedback
Can it be used as a masking
agent?
Do not include on banned
substance list
Add to banned substance list
Can it be tested for? Can cut off levels
be established?
Set levels and implement in and out of
competition testing as deemed
appropriate
Yes
Maybe
No
No
Substance in Question
Yes
Yes
Yes
No
No
Maybe
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